import Navbar from '@/components/Navbar';
import Footer from '@/components/Footer';
import { Link, useParams } from 'react-router-dom';
import { Helmet } from 'react-helmet-async';
import { ArrowLeft, ArrowRight, ExternalLink } from 'lucide-react';
import { useLanguage } from '@/contexts/LanguageContext';
import { languagePaths } from '@/lib/seo';
import { formatLanguages, getCountryBySlug, getCountryDirectory } from '@/lib/globalWebsitesData';
import { useMemo } from 'react';

type MarketSection = {
  id: string;
  title: string;
  paragraphs: string[];
};

type UaeSection = {
  id: string;
  title: string;
  paragraphs?: string[];
  bullets?: string[];
};

type FaqItem = {
  question: string;
  answer: string;
};

function buildMarketSections(countryName: string, regionName: string): MarketSection[] {
  return [
    {
      id: 'executive-summary',
      title: '1) Executive Summary',
      paragraphs: [
        `${countryName} represents a high-priority market within BioNixus' ${regionName} strategy. This market blueprint is designed as a practical operating guide for commercial leaders, medical teams, access specialists, and evidence-generation partners who need to move from broad market assumptions to disciplined execution. The objective is to create one consistent operating model that aligns market sizing, segmentation, stakeholder mapping, access logic, and launch planning into a single decision workflow rather than disconnected workstreams.`,
        `For ${countryName}, a winning strategy requires a market-specific view of demand signals, referral pathways, reimbursement pressure, and provider decision behavior. Commercial planning cannot be separated from regulatory timelines, payer logic, and local treatment protocols. This is why the framework used in this page intentionally links clinical value story, pricing narrative, channel readiness, and adoption barriers. The result is a strategy architecture that helps teams prioritize what to research first, what to validate in fieldwork, and what to convert into action in each quarter.`,
        `The recommended model for ${countryName} is evidence-led and execution-focused: define opportunity, test assumptions early, pressure-test access routes, and stage investments in line with adoption certainty. This reduces expensive late-stage pivots and improves launch confidence. Throughout this page, each section follows the same structure used across all global market pages so leadership can compare countries consistently while still respecting local market differences, language context, and operational constraints.`,
      ],
    },
    {
      id: 'market-landscape',
      title: '2) Market Landscape and Opportunity Framing',
      paragraphs: [
        `A rigorous market landscape for ${countryName} begins with a unified demand model rather than isolated volume estimates. Teams should triangulate epidemiology, diagnosis velocity, treatment eligibility, referral concentration, and provider throughput to create a realistic opportunity envelope. Overstated assumptions usually come from static prevalence figures without accounting for real-world bottlenecks such as delayed diagnosis, specialist concentration, and treatment drop-off. A credible opportunity model therefore must include pathway friction, not just disease burden.`,
        `In ${countryName}, segmentation should move beyond simple specialty labels and focus on decision ecosystems: who initiates therapy, who confirms treatment, who controls protocol access, and who influences continuation. This approach identifies practical leverage points for uptake and avoids generic messaging that does not match local clinical workflow. Market attractiveness also needs a readiness lens: data accessibility, field-force reach, institutional openness, and policy predictability all affect the speed at which opportunity can be converted into sustainable demand.`,
        `For portfolio teams, the most useful output is a staged opportunity map: immediate, medium-term, and structural upside. Immediate opportunities come from clearly identifiable patient clusters and established pathways. Medium-term opportunities are unlocked by education, pathway optimization, and access negotiations. Structural upside depends on policy shifts, infrastructure improvement, and broader diagnostic penetration. Framing ${countryName} through this staged lens allows smarter sequencing of investment and more realistic performance commitments.`,
      ],
    },
    {
      id: 'system-access',
      title: '3) Healthcare System, Access Routes, and Funding Logic',
      paragraphs: [
        `Understanding how care is delivered and financed in ${countryName} is central to any commercialization plan. Access success depends on where budget authority sits, how formularies are governed, how treatment protocols are updated, and what evidence format is considered decision-grade by local stakeholders. Teams should map institutional and payer pathways at a granular level and identify where decisions are centralized versus where local committees have practical veto power.`,
        `A common failure mode is treating reimbursement as a single event rather than a sequence. In practice, ${countryName} may require multiple gates: evidence submission, committee evaluation, protocol placement, procurement alignment, and implementation at site level. Each gate introduces timing risk and messaging requirements. The access plan must define which evidence claims are used at each stage, who owns each conversation, and what fallback options exist if timelines shift or objections emerge.`,
        `Funding architecture also shapes adoption quality. Even when formal access is achieved, utilization may remain low if operational steps are unclear for hospitals, physicians, or pharmacy teams. Therefore, market plans for ${countryName} should include implementation design: ordering flow, treatment initiation process, documentation burden, and patient follow-up mechanics. Access strategy is successful only when policy approval translates into repeatable use at point of care.`,
      ],
    },
    {
      id: 'regulatory-hta',
      title: '4) Regulatory, HTA, and Evidence Alignment',
      paragraphs: [
        `Regulatory pathway planning in ${countryName} should be integrated with pricing and market-access objectives from day one. Too often, regulatory and commercial plans are developed in parallel without shared assumptions, leading to evidence packages that satisfy technical approval requirements but leave major access questions unresolved. A better model is to define a unified evidence roadmap where clinical endpoints, economic narratives, and real-world data priorities support both approval and reimbursement outcomes.`,
        `For HTA-style evaluations or payer evidence reviews, decision-makers in ${countryName} typically need clarity on comparative value, budget impact trajectory, and expected patient-level outcomes in routine practice. This requires early design of local evidence adaptation: reference populations, local cost structures, pathway comparators, and treatment persistence assumptions. Teams should avoid direct import of global economic models without local calibration, since credibility drops quickly when assumptions do not reflect local practice.`,
        `Operationally, the most effective approach is to maintain an evidence governance cadence: periodic review of data gaps, planned analyses, stakeholder feedback, and objection patterns. In ${countryName}, this creates a living evidence system that evolves with regulatory progress and payer dialogue rather than a static submission package. The long-term advantage is not only faster initial access, but stronger resilience when re-evaluation, tender pressure, or policy updates occur.`,
      ],
    },
    {
      id: 'epidemiology-demand',
      title: '5) Epidemiology, Diagnosis Dynamics, and Demand Signals',
      paragraphs: [
        `Market demand in ${countryName} is strongly affected by diagnosis flow quality, not only prevalence. Teams should model the journey from symptom presentation to specialist confirmation, then quantify where patient leakage occurs. Key leakage points often include referral delays, uneven diagnostic capability, and variation in guideline adherence. Without this view, demand forecasts overestimate treatment-ready populations and underprepare teams for activation challenges.`,
        `A strong demand intelligence layer combines secondary data with field validation. Claims, registry, and procurement signals can indicate baseline volumes, but clinician interviews and pathway observation reveal behavioral drivers that data alone misses. In ${countryName}, teams should test assumptions around diagnosis timing, treatment eligibility criteria, and patient persistence drivers. These insights materially improve targeting, educational strategy, and early-launch expectations.`,
        `Demand signals should be monitored continuously with a practical dashboard: referral velocity, new starts, discontinuation drivers, and institution-level variation. This is especially important in ${countryName} where market conditions can shift with policy updates or provider behavior changes. Continuous monitoring turns demand planning from a one-time exercise into an execution control mechanism that supports faster tactical adjustments and better resource allocation.`,
      ],
    },
    {
      id: 'stakeholder-kol',
      title: '6) Stakeholder Mapping and KOL Influence Networks',
      paragraphs: [
        `Effective engagement in ${countryName} depends on understanding influence networks, not just creating a list of senior experts. True influence may come from protocol authors, referral gatekeepers, institutional champions, payer-facing clinicians, and multidisciplinary committees. Stakeholder mapping should classify both formal authority and informal credibility, then connect each stakeholder to specific decisions in the adoption pathway.`,
        `KOL strategy for ${countryName} should include clear engagement objectives by phase: evidence interpretation, pathway education, access support, and implementation optimization. Each objective requires a different interaction format and supporting material. For example, early-stage engagements may prioritize unmet need framing and patient identification barriers, while later-stage discussions focus on treatment sequencing, practical implementation, and outcomes tracking.`,
        `High-performing teams also track stakeholder sentiment changes over time. In ${countryName}, stakeholder confidence is influenced by local experience, peer endorsement, and operational ease at site level. A structured listening loop that captures objections, evidence requests, and adoption friction enables faster messaging refinement and stronger relationships. Stakeholder strategy is most valuable when it functions as a decision intelligence engine, not just a relationship list.`,
      ],
    },
    {
      id: 'provider-channel',
      title: '7) Provider, Institution, and Channel Readiness',
      paragraphs: [
        `Provider and institution readiness in ${countryName} should be assessed as an operational system: awareness, protocol fit, procurement path, pharmacy workflow, and follow-up capability. Even with strong clinical interest, adoption can stall when one operational node fails. Therefore, readiness scoring should be done at account level and include both clinical and administrative dimensions so deployment resources can be prioritized where conversion potential is highest.`,
        `Channel strategy in ${countryName} must reflect who actually controls therapy flow. In some contexts, specialist centers drive treatment initiation while peripheral institutions handle continuation; in others, procurement structure and distribution design shape practical availability. Commercial and medical teams should align account strategy with real-world channel mechanics rather than theoretical pathway maps. This alignment prevents misallocation of field activity and reduces time-to-activation.`,
        `Readiness programs should include practical enablement assets: implementation checklists, role-specific training, referral support materials, and post-initiation tracking templates. In ${countryName}, these assets help convert policy or protocol inclusion into day-to-day use. The key metric is not only account coverage, but activation depth: the proportion of prioritized accounts that can independently identify, initiate, and maintain appropriate patients.`,
      ],
    },
    {
      id: 'competitive-intelligence',
      title: '8) Competitive, Pipeline, and Strategic Positioning',
      paragraphs: [
        `Competitive intelligence in ${countryName} should cover current standards of care, emerging alternatives, substitution risks, and likely pricing responses. A static competitor profile is not enough; teams need scenario-based intelligence that anticipates how competitor moves will influence payer preferences, clinician behavior, and patient flow. This requires continuous monitoring of trial activity, guideline discussion, local partnerships, and market access tactics.`,
        `Positioning strategy should articulate where the offer is superior, where parity is acceptable, and where mitigation is needed. In ${countryName}, credible positioning balances clinical differentiation with practical benefits such as pathway simplicity, implementation support, and predictable budget impact. Overclaiming differentiation can reduce trust; under-communicating practical value can slow adoption. The strongest position integrates evidence strength with operational relevance.`,
        `Pipeline monitoring should also inform investment timing. If near-term entrants are likely in ${countryName}, launch sequencing, account prioritization, and evidence communication need to accelerate in strategic segments. Conversely, if the competitive window is wider, teams can build deeper ecosystem readiness before scaling. Competitive strategy is therefore not a separate stream; it should directly shape field deployment, evidence cadence, and partnership planning.`,
      ],
    },
    {
      id: 'go-to-market',
      title: '9) Go-to-Market Architecture and Launch Sequencing',
      paragraphs: [
        `A robust go-to-market model for ${countryName} starts with phased deployment rather than full-market activation. Phase one should focus on high-readiness institutions and clearly defined patient segments, generating proof of execution and local case confidence. Phase two scales into adjacent accounts with tailored support based on lessons from early sites. Phase three expands through broader ecosystem partnerships and pathway optimization, supported by accumulated local evidence.`,
        `Launch sequencing should be governed by measurable readiness gates: account qualification, stakeholder alignment, access progress, and operational capability. In ${countryName}, this gate approach prevents premature scaling that inflates cost without durable uptake. Each phase should define expected outputs, risk indicators, and decision thresholds for progression. This creates transparency for leadership and enables disciplined resource deployment across commercial, medical, and market access teams.`,
        `Cross-functional alignment is the main predictor of launch quality. Teams in ${countryName} should operate through a single launch control room with shared metrics and weekly decision routines. Commercial activity, evidence updates, stakeholder sentiment, and access progress must be reviewed together to avoid fragmented responses. With this governance model, market execution becomes adaptive and resilient instead of reactive and siloed.`,
      ],
    },
    {
      id: 'evidence-heor',
      title: '10) Real-World Evidence, HEOR, and Outcomes Strategy',
      paragraphs: [
        `In ${countryName}, real-world evidence should be planned as a staged program aligned to value questions from clinicians, payers, and institutional decision-makers. Early evidence often needs to demonstrate practical feasibility and patient identification quality. Mid-stage evidence should validate outcome consistency and treatment persistence. Later evidence can focus on comparative effectiveness, cost trajectories, and pathway optimization opportunities.`,
        `HEOR design must be locally meaningful. Budget impact and value claims should be built with assumptions that reflect ${countryName}'s treatment pathways, cost structures, and care delivery patterns. Teams should pre-test model assumptions with local experts to ensure relevance and defensibility. Transparent assumptions and sensitivity analyses improve trust and reduce pushback during payer or committee discussions.`,
        `Outcomes strategy should include implementation metrics, not only clinical endpoints. For ${countryName}, tracking referral quality, initiation lag, adherence patterns, and discontinuation reasons can identify operational bottlenecks that limit realized value. Embedding these metrics into market governance helps teams convert evidence generation into actionable optimization, strengthening both short-term adoption and long-term market positioning.`,
      ],
    },
    {
      id: 'risk-governance',
      title: '11) Risk Management, Compliance, and Governance',
      paragraphs: [
        `Sustainable growth in ${countryName} requires proactive risk management across regulatory, operational, reputational, and commercial dimensions. Teams should maintain a risk register linked to mitigation owners and escalation thresholds. Typical risk categories include evidence misalignment, access delay, procurement disruption, field execution inconsistency, and stakeholder miscommunication. A visible risk governance routine reduces surprise and improves decision speed.`,
        `Compliance frameworks should be embedded into engagement design from the start. In ${countryName}, this means ensuring medical-commercial boundaries are clear, promotional standards are respected, data handling is secure, and third-party interactions follow local rules. Compliance-by-design protects both brand trust and execution continuity. It also enables teams to move faster because guardrails are pre-defined rather than interpreted ad hoc.`,
        `Governance cadence should combine strategic and operational views: monthly leadership steering for direction, weekly cross-functional operations for execution, and rapid-response pathways for emergent issues. For ${countryName}, this layered governance model ensures decisions remain aligned with market reality while preserving strategic consistency. Governance is most effective when it is data-informed, accountable, and tightly connected to execution outcomes.`,
      ],
    },
    {
      id: 'action-plan',
      title: '12) 12-Month Action Plan for Market Execution',
      paragraphs: [
        `Months 1-3 in ${countryName} should focus on baseline validation: refine demand model, prioritize target accounts, confirm stakeholder map, and finalize evidence priorities by decision gate. The primary output is a validated launch blueprint with explicit assumptions and quantified risks. Teams should also complete operational readiness checks across account onboarding, documentation flow, and follow-up pathways to prevent avoidable friction during activation.`,
        `Months 4-8 should prioritize controlled activation. Launch in highest-readiness accounts, monitor conversion and persistence indicators weekly, and adjust engagement tactics based on stakeholder feedback. In ${countryName}, this phase is where field insights must directly shape messaging and support assets. Access progress, account activation depth, and early outcomes should be reviewed in one integrated dashboard to maintain alignment across functions.`,
        `Months 9-12 should transition from activation to scale with discipline. Expand into adjacent segments only where readiness thresholds are met, reinforce successful account models, and formalize evidence outputs that strengthen market credibility. For ${countryName}, the year-one objective is not maximum spread but durable momentum: predictable initiation flow, stable continuation patterns, and a governance model capable of supporting long-term growth.`,
      ],
    },
  ];
}

function countWords(text: string) {
  return text.trim().split(/\s+/).filter(Boolean).length;
}

const UAE_FAQS = [
  {
    question: 'What is the typical sample size for UAE physician research?',
    answer:
      'Quantitative studies usually range from n=50 for niche specialties to n=200+ for broader physician segments. Qualitative programs often reach thematic saturation with 10-15 in-depth interviews.',
  },
  {
    question: 'How do you access physicians in SEHA hospitals?',
    answer:
      'We use institutional partnerships, medical conference recruitment, and physician society channels, with the required ethics and facility-level approvals managed as part of execution.',
  },
  {
    question: 'Is Arabic-language research necessary in the UAE?',
    answer:
      'English is common in clinical settings, but Arabic modules are important for Emirati physician segments, patient studies, and pharmacy-level research. We support both languages.',
  },
  {
    question: 'What is the MOHAP registration timeline for pharmaceuticals?',
    answer:
      'Typical timelines are around 6-12 months depending on therapy class, dossier complexity, local evidence needs, and pricing or reimbursement negotiations.',
  },
];

const SAUDI_FAQS = [
  {
    question: 'What is the typical sample size for Saudi physician research?',
    answer:
      'Quantitative studies typically range from n=75 to n=300+ depending on specialty and region. Qualitative programs usually require 12-18 interviews for saturation across Riyadh, Jeddah, and Eastern Province.',
  },
  {
    question: 'How do you access physicians in MOH hospitals and medical cities?',
    answer:
      'We combine SCFHS-aligned recruitment channels, institutional approvals, conference-based outreach, and specialty society networks with region-specific validation protocols.',
  },
  {
    question: 'How long does SFDA registration usually take?',
    answer:
      'Standard pathways are often 12-18 months, while expedited or priority pathways may move faster depending on therapy class, evidence package quality, and pricing negotiation complexity.',
  },
  {
    question: 'What is unique about NUPCO in Saudi market access?',
    answer:
      'NUPCO central procurement strongly shapes public-sector uptake through tender cycles, pricing pressure, and contract terms, making tender intelligence and access sequencing critical.',
  },
];

const US_FAQS = [
  {
    question: 'How do you verify US physicians for research quality?',
    answer:
      'We validate respondents using NPI and licensure checks, specialty and patient-volume screening, and post-field quality controls to reduce low-quality professional respondent risk.',
  },
  {
    question: 'What sample sizes are typical for US physician studies?',
    answer:
      'Quantitative studies usually range from n=150 to n=750 by specialty rarity and segmentation depth, while qualitative KOL programs often use 12-20 interviews for robust insight saturation.',
  },
  {
    question: 'Can BioNixus support payer and formulary intelligence in the US?',
    answer:
      'Yes. We conduct payer and market-access research across Medicare, Medicaid, commercial plans, PBMs, and IDN decision structures to inform access sequencing and value narrative design.',
  },
  {
    question: 'Do you support launch strategy and competitive tracking?',
    answer:
      'Yes. We combine awareness tracking, message testing, segment analytics, and competitive intelligence to optimize launch readiness and early adoption in the US market.',
  },
];

const UK_FAQS = [
  {
    question: 'How do you recruit NHS consultants and UK specialists for research?',
    answer:
      'We use specialty-network recruitment, verified clinician panels, and flexible interview scheduling with strict quality controls and GMC-aware screening patterns for participant validation.',
  },
  {
    question: 'How long does MHRA-to-NICE access usually take?',
    answer:
      'Typical access journeys range from around 6 to 18 months depending on appraisal pathway, evidence maturity, and regional formulary adoption dynamics across UK systems.',
  },
  {
    question: 'Do you support NICE, SMC, and AWMSG evidence planning?',
    answer:
      'Yes. We support UK-wide access strategy with England-focused NICE pathways plus Scotland and Wales appraisal considerations to improve sequencing and submission readiness.',
  },
  {
    question: 'Can BioNixus cover both NHS and private UK channels?',
    answer:
      'Yes. We design integrated UK research models across NHS and private providers to capture realistic prescribing, referral, and adoption behavior by setting.',
  },
];

const GERMANY_FAQS = [
  {
    question: 'How do you recruit physicians across Germany for pharma research?',
    answer:
      'We use specialty-targeted recruitment, verified clinician networks, and structured quality controls across university hospitals, regional clinics, and office-based practices.',
  },
  {
    question: 'How does Germany market access differ from other EU markets?',
    answer:
      'Germany combines rapid launch opportunity with post-launch evidence and pricing pressure under AMNOG/G-BA processes, so sequencing and value narrative design are critical.',
  },
  {
    question: 'Do you support AMNOG and HTA evidence strategy?',
    answer:
      'Yes. We support evidence planning and stakeholder intelligence for AMNOG-aligned positioning, comparator logic, and practical adoption pathways.',
  },
  {
    question: 'Can BioNixus cover both hospital and office-based channels in Germany?',
    answer:
      'Yes. We design integrated studies across inpatient, outpatient, and specialist-office pathways to reflect real prescribing and referral behavior.',
  },
];

const FRANCE_FAQS = [
  {
    question: 'How do you recruit physicians and specialists across France?',
    answer:
      'We combine specialty-led recruitment with verified clinician networks and strict quality controls across CHU centers, regional hospitals, and office-based specialists.',
  },
  {
    question: 'How is market access structured in France for new therapies?',
    answer:
      'Access planning requires alignment to HAS evaluation, CEPS pricing logic, and practical hospital or community adoption dynamics, so evidence strategy and sequencing are essential.',
  },
  {
    question: 'Can BioNixus support HTA and reimbursement intelligence in France?',
    answer:
      'Yes. We support HTA-aware evidence planning, stakeholder insight, and market access strategy to strengthen launch preparation and post-launch optimization.',
  },
  {
    question: 'Do you cover both hospital and ambulatory channels in France?',
    answer:
      'Yes. We design integrated research models spanning inpatient and ambulatory pathways to capture realistic prescribing, referral, and treatment continuation behavior.',
  },
];

const SPAIN_FAQS = [
  {
    question: 'How do you recruit physicians and specialists across Spain?',
    answer:
      'We combine specialty-focused recruitment with verified clinician networks and quality controls across tertiary hospitals, regional centers, and office-based practices.',
  },
  {
    question: 'How is market access typically structured in Spain?',
    answer:
      'Access planning requires national and regional awareness, with evidence strategy aligned to HTA and payer expectations plus practical implementation realities.',
  },
  {
    question: 'Can BioNixus support HTA and reimbursement intelligence for Spain?',
    answer:
      'Yes. We support evidence planning, stakeholder mapping, and access strategy to improve launch sequencing and adoption confidence in Spain.',
  },
  {
    question: 'Do you cover both hospital and outpatient channels in Spain?',
    answer:
      'Yes. We build integrated studies across hospital and outpatient pathways to capture realistic prescribing, referral, and treatment continuation behavior.',
  },
];

const ITALY_FAQS = [
  {
    question: 'How do you recruit physicians and specialists across Italy?',
    answer:
      'We combine specialty-focused recruitment with verified clinician networks and quality controls across university hospitals, regional systems, and office-based specialists.',
  },
  {
    question: 'How is pharmaceutical market access structured in Italy?',
    answer:
      'Access strategy requires alignment to AIFA and regional implementation dynamics, with evidence planning tailored to practical reimbursement and formulary pathways.',
  },
  {
    question: 'Can BioNixus support HTA and reimbursement intelligence in Italy?',
    answer:
      'Yes. We support HTA-aware evidence planning, stakeholder mapping, and market-access strategy for launch sequencing and post-launch optimization.',
  },
  {
    question: 'Do you cover hospital and outpatient channels in Italy?',
    answer:
      'Yes. We run integrated studies across inpatient and outpatient pathways to capture realistic prescribing, referral, and adoption behavior.',
  },
];

const KUWAIT_FAQS = [
  {
    question: 'How do you recruit physicians across Kuwait for pharma research?',
    answer:
      'We combine MOH and private-sector recruitment with verified clinician networks and quality controls across major hospitals, specialty centers, and private clinics.',
  },
  {
    question: 'Can BioNixus support KFDA and MOH market-access strategy?',
    answer:
      'Yes. We support KFDA-aware evidence planning, MOH formulary and tender intelligence, and practical access sequencing for launch and lifecycle strategy.',
  },
  {
    question: 'Do you cover both public and private healthcare channels in Kuwait?',
    answer:
      'Yes. We run integrated research across MOH facilities and private providers to reflect differences in prescribing, referral pathways, and adoption behavior.',
  },
  {
    question: 'How does Kuwait fit into broader GCC expansion plans?',
    answer:
      'Kuwait is a strategic GCC market with strong regulatory and procurement signals, making it valuable for evidence generation and regional rollout planning.',
  },
];

const QATAR_FAQS = [
  {
    question: 'How do you recruit physicians and specialists across Qatar?',
    answer:
      'We combine public and private healthcare recruitment with verified clinician networks and quality controls across major hospitals, specialty centers, and private clinics.',
  },
  {
    question: 'Can BioNixus support market-access strategy in Qatar?',
    answer:
      'Yes. We support regulatory-aware evidence planning, formulary intelligence, and stakeholder sequencing to improve launch readiness and adoption outcomes in Qatar.',
  },
  {
    question: 'Do you cover both public and private healthcare channels in Qatar?',
    answer:
      'Yes. We run integrated studies across public institutions and private providers to capture differences in prescribing behavior, referral pathways, and treatment access.',
  },
  {
    question: 'How does Qatar fit into GCC pharmaceutical expansion plans?',
    answer:
      'Qatar is a high-value GCC market with advanced healthcare infrastructure, making it strategically important for cross-country evidence generation and regional scaling.',
  },
];

const BAHRAIN_FAQS = [
  {
    question: 'How do you recruit physicians and specialists across Bahrain?',
    answer:
      'We combine targeted recruitment and verified clinician networks across public hospitals, private facilities, and specialty clinics with strict quality controls.',
  },
  {
    question: 'Can BioNixus support reimbursement and access strategy in Bahrain?',
    answer:
      'Yes. We support market-access evidence planning, stakeholder mapping, and formulary intelligence to improve launch sequencing and adoption outcomes.',
  },
  {
    question: 'Do you cover both government and private healthcare channels in Bahrain?',
    answer:
      'Yes. We run integrated studies across public and private settings to reflect real-world differences in prescribing, referral, and therapy uptake.',
  },
  {
    question: 'How does Bahrain support broader GCC market planning?',
    answer:
      'Bahrain offers a strategic GCC test-and-scale environment with valuable insight for regional positioning, access planning, and lifecycle optimization.',
  },
];

const OMAN_FAQS = [
  {
    question: 'How do you recruit physicians and specialists across Oman?',
    answer:
      'We use specialty-focused recruitment and validated clinician networks across MOH hospitals, regional facilities, and private providers with robust quality controls.',
  },
  {
    question: 'Can BioNixus support market-access strategy in Oman?',
    answer:
      'Yes. We support regulatory-aware evidence planning, payer and stakeholder intelligence, and formulary strategy for launch and lifecycle decisions in Oman.',
  },
  {
    question: 'Do you cover both public and private healthcare channels in Oman?',
    answer:
      'Yes. We design integrated studies across public hospitals, specialist centers, and private clinics to capture practical pathway and adoption dynamics.',
  },
  {
    question: 'How does Oman contribute to GCC pharmaceutical strategy?',
    answer:
      'Oman offers important access and implementation insights for GCC portfolios, especially for teams optimizing sequencing across multiple Gulf markets.',
  },
];

const EGYPT_FAQS = [
  {
    question: 'How do you recruit physicians and hospitals across Egypt for research?',
    answer:
      'We combine specialty-led physician recruitment, hospital stakeholder outreach, and strict quality controls across university hospitals, MOH networks, and private providers.',
  },
  {
    question: 'Can BioNixus support MOH and Universal Health Insurance market-access strategy?',
    answer:
      'Yes. We support MOH-aware and UHI-informed evidence planning, stakeholder mapping, and access strategy to improve formulary and adoption readiness.',
  },
  {
    question: 'Do you provide diagnostics and laboratory network research in Egypt?',
    answer:
      'Yes. We run diagnostics-focused studies across leading laboratory chains and provider networks to support prevalence, pathway, and testing-behavior analysis.',
  },
  {
    question: 'How does Egypt support broader MENA pharmaceutical strategy?',
    answer:
      'Egypt provides scale, Arabic-language depth, and strong academic-medical infrastructure, making it a practical hub for evidence generation that can inform adjacent MENA markets.',
  },
];

function buildGenericFaq(countryName: string): FaqItem[] {
  return [
    {
      question: `How quickly can BioNixus start market research in ${countryName}?`,
      answer:
        'Most projects can start within 1-2 weeks after scope alignment. Timelines depend on respondent complexity, regulatory context, and required evidence depth.',
    },
    {
      question: `What methods are used in ${countryName} projects?`,
      answer:
        'We combine quantitative surveys, qualitative interviews, stakeholder mapping, and market-access evidence workflows to match your decision priorities.',
    },
    {
      question: `Do you support both local and international stakeholder perspectives in ${countryName}?`,
      answer:
        'Yes. We map local treatment pathways and institutional decision points while also benchmarking cross-market dynamics for regional or global teams.',
    },
    {
      question: `Can BioNixus support market access and pricing strategy in ${countryName}?`,
      answer:
        'Yes. We design evidence generation and payer-facing insight programs that help teams prioritize pricing logic, reimbursement narratives, and adoption planning.',
    },
  ];
}

const UAE_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'UAE Pharmaceutical Market at a Glance',
    bullets: [
      'Market value: AED 17.8 billion (USD 4.8B) pharmaceutical market (2024)',
      'Growth rate: 8.2% CAGR (2024-2028), above global average',
      'Hospital infrastructure: 160+ public and private hospitals; 3,800+ pharmacies',
      'Medical tourism: 500,000+ international patients annually driving specialty demand',
      'Regulatory bodies: DHA (Dubai), MOHAP (federal), DOH (Abu Dhabi)',
    ],
    paragraphs: [
      'The UAE pharmaceutical market is one of the most execution-ready healthcare environments in MENA, with concentrated specialist hubs in Dubai and Abu Dhabi, high private insurance penetration, and strong infrastructure for advanced therapies.',
      'Commercial strategy in the Emirates requires emirate-specific design: Dubai dynamics differ from Abu Dhabi and Northern Emirates in provider mix, payer behavior, and institutional adoption pathways.',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive UAE Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP surveys across public and private systems',
      'Qualitative KOL interviews and multi-stakeholder focus groups',
      'MOHAP and payer-aligned market access and pricing intelligence',
      'KOL and influence-network mapping by therapeutic area and emirate',
      'Pharmacy channel studies across chain and independent networks',
    ],
    paragraphs: [
      'BioNixus combines quantitative and qualitative methods to produce decision-ready evidence for launch planning, market access, and lifecycle optimization in the UAE.',
      'Programs are built for practical execution: sample design, stakeholder prioritization, evidence packaging, and implementation support are aligned to the same decision framework.',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'UAE Healthcare System Coverage',
    bullets: [
      'Dubai: Dubai Healthcare City, Mediclinic network, NMC, key DHA institutions',
      'Abu Dhabi: SEHA network, Cleveland Clinic Abu Dhabi, Burjeel, SSMC',
      'Northern Emirates: Sharjah, RAK, Ajman, Fujairah, and related provider clusters',
    ],
  },
  {
    id: 'compliance',
    title: 'Regulatory and Compliance Framework',
    bullets: [
      'DHA, MOHAP, and DOH alignment for study design and execution',
      'ICH-GCP standards and local ethics expectations',
      'Arabic and English informed consent and field protocols',
      'Enterprise-grade data security and privacy controls',
    ],
    paragraphs: [
      'Our UAE market research model is designed for compliance-by-default, so evidence quality and governance expectations are met from recruitment through reporting.',
    ],
  },
  {
    id: 'methodology',
    title: 'UAE Field Methodology',
    bullets: [
      'License-verified physician recruitment (DHA and MOHAP practitioner checks)',
      'Modes: online, CATI, and targeted face-to-face in major emirates',
      'Arabic-speaking interviewer support where required',
      'Quality controls: attention checks, geolocation logic, and callback audits',
      'Segmentation: emirate, public vs. private, specialist vs. PCP, payer context',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in the UAE',
    bullets: [
      'Oncology and specialty access pathways',
      'Diabetes and metabolic disorders with high-prevalence dynamics',
      'Cardiovascular treatment and technology adoption patterns',
      'Rare diseases and orphan-access barriers',
      'Respiratory care and biologic adoption trends',
    ],
  },
];

const SAUDI_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'Saudi Arabia Pharmaceutical Market at a Glance',
    bullets: [
      'Market value: SAR 42.6 billion (USD 11.4B) pharmaceutical market (2024)',
      'Growth rate: 9.1% CAGR (2024-2028), among the fastest in GCC',
      'Vision 2030 target: 40% local pharmaceutical manufacturing by 2030',
      'Infrastructure: 500+ MOH hospitals, 180+ private hospitals, 2,400+ PHCs',
      'Core authorities: SFDA regulation, NUPCO procurement, MOH reimbursement pathways',
    ],
    paragraphs: [
      'Saudi Arabia is a scale market where access strategy, institutional sequencing, and regional execution quality determine launch performance more than headline demand alone.',
      'Winning execution requires explicit alignment to SFDA pathways, NUPCO dynamics, and Vision 2030 healthcare transformation priorities.',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive Saudi Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across MOH, military, and private systems',
      'Qualitative KOL interviews and multi-stakeholder research',
      'SFDA and NUPCO-aligned market access intelligence',
      'KOL mapping across Riyadh, Jeddah, Dammam, and key regions',
      'Pharmacy channel and payer intelligence for public and private sectors',
    ],
  },
  {
    id: 'vision-2030',
    title: 'Vision 2030 Healthcare Transformation Signals',
    bullets: [
      'Privatization and public-private operating model shifts',
      'Local manufacturing and partnership opportunities',
      'Insurance expansion and changing reimbursement behavior',
      'Clinical research ecosystem growth and data readiness',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'Saudi Healthcare Coverage Footprint',
    bullets: [
      'Central: Riyadh medical cities and national referral institutions',
      'Western: Jeddah and Makkah region provider networks',
      'Eastern: Dammam, Al Khobar, and major specialist centers',
      'Southern and Northern regions: strategic MOH and military care sites',
    ],
  },
  {
    id: 'compliance',
    title: 'Saudi Compliance and Evidence Framework',
    bullets: [
      'SFDA-aligned evidence and registration support logic',
      'MOH and institutional ethics pathways',
      'Arabic and English field protocols with cultural-fit execution',
      'PDPL-aware data handling and enterprise security controls',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in Saudi Arabia',
    bullets: [
      'Oncology and biosimilar adoption pathways',
      'Diabetes and metabolic disease opportunity clusters',
      'Cardiovascular, rare disease, respiratory, and hepatology priorities',
      'Regional KOL influence mapping by specialty and institution',
    ],
  },
];

const US_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'US Pharmaceutical Market at a Glance',
    bullets: [
      'Market value: USD 600+ billion pharmaceutical market, the largest globally',
      'Specialty and biologic therapies are major growth drivers in launch planning',
      'Complex access landscape across Medicare, Medicaid, commercial, and PBM channels',
      'Physician influence is fragmented across AMCs, IDNs, and community practice',
      'FDA pathway, payer evidence, and commercial sequencing must be aligned early',
    ],
    paragraphs: [
      'The United States market rewards precision execution: clinical differentiation alone is not enough without access-fit evidence and practical implementation design.',
      'High-performing launch strategies integrate physician behavior, payer dynamics, and channel readiness from day one.',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive US Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across specialties and settings',
      'KOL interviews, advisory boards, and treatment pathway deep-dives',
      'US payer and PBM intelligence for market access and reimbursement strategy',
      'Launch analytics, messaging optimization, and competitive tracking',
      'Patient and real-world evidence insight programs for adherence and outcomes',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'US Healthcare System Coverage',
    bullets: [
      'Northeast: AMC concentration and high commercial-plan density',
      'Southeast: mixed Medicare/Medicaid and strong community networks',
      'Midwest: IDN and regional KOL influence on adoption speed',
      'West and Southwest: managed care concentration and specialty growth hubs',
    ],
  },
  {
    id: 'compliance',
    title: 'US Regulatory and Compliance Framework',
    bullets: [
      'FDA pathway and evidence-planning intelligence',
      'HIPAA-aware data handling and patient privacy safeguards',
      'IRB-aligned ethics workflows with accredited partner networks',
      'ICH-GCP standards and enterprise-grade security controls',
    ],
  },
  {
    id: 'methodology',
    title: 'US Field Methodology',
    bullets: [
      'Multi-channel physician recruitment across specialty and society networks',
      'NPI/licensure verification and respondent quality controls',
      'Online, phone, and mixed-method deployment by study objective',
      'Advanced analytics: segmentation, conjoint, and adoption forecasting',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in the United States',
    bullets: [
      'Oncology, cardiology, and metabolic care pathways',
      'Neurology, immunology, and inflammatory diseases',
      'Rare disease adoption dynamics and patient identification strategy',
      'Cross-specialty access barriers and value narrative optimization',
    ],
  },
];

const UK_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'UK Pharmaceutical Market at a Glance',
    bullets: [
      'Market value: GBP 25.3 billion pharmaceutical market with strong specialty momentum',
      'NHS remains the dominant channel while private care adds strategic acceleration points',
      'Regulatory and access pathways require MHRA, NICE, and regional appraisal awareness',
      'Integrated care structures and formulary layers shape practical adoption speed',
      'Execution quality depends on aligning evidence, payer logic, and provider behavior',
    ],
    paragraphs: [
      'The UK market combines scientific rigor with system complexity, making evidence design and access sequencing central to commercial outcomes.',
      'Winning strategy links clinical credibility with practical NHS and private-channel implementation planning.',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive UK Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across NHS and private settings',
      'KOL interviews and qualitative pathway intelligence',
      'NICE and market-access evidence planning support',
      'Regional adoption insight across England, Scotland, Wales, and Northern Ireland',
      'Launch analytics and stakeholder influence mapping by specialty',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'UK Healthcare System Coverage',
    bullets: [
      'England: major teaching-hospital and regional trust ecosystems',
      'Scotland: health-board and appraisal-specific strategic requirements',
      'Wales and Northern Ireland: localized decision and implementation dynamics',
      'Private provider groups for rapid adoption and channel benchmarking',
    ],
  },
  {
    id: 'compliance',
    title: 'UK Regulatory and Compliance Framework',
    bullets: [
      'MHRA-informed regulatory strategy and post-approval planning',
      'NICE-aligned evidence narratives for reimbursement pathways',
      'NHS research ethics and governance process awareness',
      'GDPR-compliant data controls and ICH-GCP standards',
    ],
  },
  {
    id: 'methodology',
    title: 'UK Field Methodology',
    bullets: [
      'GMC-aware physician validation and specialty targeting',
      'Online, CATI, and targeted interview modes by objective',
      'NHS and private sector sample balancing for realistic insight',
      'Advanced analytics for segmentation, access barriers, and adoption drivers',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in the United Kingdom',
    bullets: [
      'Oncology and precision-medicine access pathways',
      'Cardiology and metabolic burden management trends',
      'Neurology, respiratory, immunology, and rare disease strategy',
      'Specialty-area evidence design for appraisal and uptake confidence',
    ],
  },
];

const GERMANY_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'Germany Pharmaceutical Market at a Glance',
    bullets: [
      'Germany is one of Europe\'s largest pharmaceutical markets with strong innovation uptake',
      'Early-launch potential is high, followed by structured HTA and pricing reassessment',
      'Hospital and office-based care pathways require differentiated execution',
      'Payer, physician, and federal-institution dynamics jointly shape adoption speed',
      'Commercial success depends on aligning clinical value with reimbursement logic',
    ],
    paragraphs: [
      'Germany rewards teams that combine launch speed with disciplined post-launch evidence and access planning.',
      'A practical market strategy must connect product differentiation, comparator narrative, and account-level implementation.',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive Germany Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across major specialties and settings',
      'Qualitative KOL interviews and clinical pathway intelligence',
      'AMNOG and market-access evidence support',
      'Hospital vs. ambulatory channel segmentation and adoption analysis',
      'Launch analytics, message optimization, and competitive tracking',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'Germany Healthcare Coverage Footprint',
    bullets: [
      'Major university hospital hubs and high-volume specialty centers',
      'Regional coverage across federal states with varied prescribing dynamics',
      'Office-based specialist and ambulatory care pathways',
      'Cross-channel insight from tertiary to community settings',
    ],
  },
  {
    id: 'compliance',
    title: 'Germany Compliance and Evidence Framework',
    bullets: [
      'AMNOG and G-BA-aware evidence strategy',
      'ICH-GCP standards and local ethics alignment',
      'GDPR-compliant data governance and security controls',
      'Structured quality validation for physician and stakeholder samples',
    ],
  },
  {
    id: 'methodology',
    title: 'Germany Field Methodology',
    bullets: [
      'Specialty-specific recruitment with credential and response-quality checks',
      'Online, phone, and expert-interview deployment by objective',
      'Segmentation by setting, specialty, and regional treatment behavior',
      'Analytics for adoption barriers, positioning, and launch readiness',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in Germany',
    bullets: [
      'Oncology and precision medicine implementation pathways',
      'Cardiometabolic and chronic-care optimization opportunities',
      'Neurology, immunology, and rare disease access dynamics',
      'Comparator-sensitive positioning in high-evidence specialties',
    ],
  },
];

const FRANCE_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'France Pharmaceutical Market at a Glance',
    bullets: [
      'France is a major EU pharmaceutical market with strong public-system influence',
      'Launch potential is shaped by HTA, pricing, and regional implementation realities',
      'Hospital and ambulatory pathways require differentiated access tactics',
      'Clinical value communication must align with reimbursement expectations',
      'Commercial outcomes improve when evidence and account execution are integrated',
    ],
    paragraphs: [
      'France rewards teams that connect clinical differentiation with practical access and implementation planning.',
      'A high-performing strategy links stakeholder evidence, HTA context, and field execution discipline.',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive France Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across major specialties and settings',
      'Qualitative KOL interviews and treatment-pathway intelligence',
      'HAS and reimbursement-aware market-access evidence support',
      'Hospital vs. ambulatory channel segmentation and adoption analysis',
      'Launch analytics, message testing, and competitive intelligence',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'France Healthcare Coverage Footprint',
    bullets: [
      'Coverage across major CHU hubs and key regional clinical networks',
      'Public-hospital and specialist-office channel representation',
      'Cross-region insight for differing implementation and adoption patterns',
      'Integrated coverage from tertiary centers to routine care pathways',
    ],
  },
  {
    id: 'compliance',
    title: 'France Compliance and Evidence Framework',
    bullets: [
      'HAS-aware evidence strategy and reimbursement context support',
      'ICH-GCP standards and local ethics alignment',
      'GDPR-compliant data governance and security controls',
      'Structured quality validation for clinician and stakeholder samples',
    ],
  },
  {
    id: 'methodology',
    title: 'France Field Methodology',
    bullets: [
      'Specialty-specific recruitment and credential checks',
      'Online, phone, and expert-interview deployment by objective',
      'Segmentation by setting, specialty, and regional behavior patterns',
      'Analytics for adoption barriers, positioning, and launch readiness',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in France',
    bullets: [
      'Oncology and specialty-care adoption pathways',
      'Cardiometabolic and chronic-care optimization opportunities',
      'Neurology, immunology, and rare disease access dynamics',
      'Comparator-sensitive evidence positioning in high-priority areas',
    ],
  },
];

const SPAIN_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'Spain Pharmaceutical Market at a Glance',
    bullets: [
      'Spain is a large EU pharmaceutical market with strong public-system influence',
      'Market success depends on balancing national strategy with regional execution',
      'Hospital and outpatient pathways require differentiated access planning',
      'Stakeholder evidence and value communication must align with reimbursement logic',
      'Commercial outcomes improve when access and field activation are integrated',
    ],
    paragraphs: [
      'Spain rewards teams that connect robust evidence with practical, region-aware implementation.',
      'Effective strategy aligns stakeholder priorities, access sequencing, and execution discipline from launch through scale.',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive Spain Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across key specialties and care settings',
      'Qualitative KOL interviews and treatment-pathway intelligence',
      'HTA and reimbursement-aware market-access evidence support',
      'Hospital vs. outpatient channel segmentation and adoption analysis',
      'Launch analytics, message optimization, and competitive intelligence',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'Spain Healthcare Coverage Footprint',
    bullets: [
      'Coverage across major hospital hubs and regional healthcare systems',
      'Public and private setting representation for practical market insight',
      'Cross-region perspective for varied implementation and uptake patterns',
      'Integrated coverage from tertiary centers to community pathways',
    ],
  },
  {
    id: 'compliance',
    title: 'Spain Compliance and Evidence Framework',
    bullets: [
      'HTA-aware evidence strategy and reimbursement context support',
      'ICH-GCP standards and local ethics alignment',
      'GDPR-compliant data governance and security controls',
      'Structured quality validation for clinician and stakeholder samples',
    ],
  },
  {
    id: 'methodology',
    title: 'Spain Field Methodology',
    bullets: [
      'Specialty-targeted recruitment and credential validation',
      'Online, phone, and expert-interview modes matched to objectives',
      'Segmentation by setting, specialty, and regional adoption dynamics',
      'Analytics for positioning, access barriers, and launch readiness',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in Spain',
    bullets: [
      'Oncology and specialty-care adoption pathways',
      'Cardiometabolic and chronic-care optimization opportunities',
      'Neurology, immunology, and rare disease access dynamics',
      'Comparator-sensitive positioning in priority therapeutic segments',
    ],
  },
];

const ITALY_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'Italy Pharmaceutical Market at a Glance',
    bullets: [
      'Italy is a major EU pharmaceutical market with strong regional-system variation',
      'Commercial execution depends on aligning national strategy with regional access realities',
      'Hospital and territorial care pathways require differentiated activation models',
      'Clinical value communication must connect with reimbursement and formulary logic',
      'Adoption improves when evidence generation and account execution are integrated',
    ],
    paragraphs: [
      'Italy rewards teams that combine robust clinical evidence with practical region-specific implementation.',
      'A high-performing strategy aligns stakeholder insight, HTA context, and disciplined launch operations.',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive Italy Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across major specialties and settings',
      'Qualitative KOL interviews and treatment-pathway intelligence',
      'AIFA and reimbursement-aware market-access evidence support',
      'Hospital vs. outpatient channel segmentation and adoption analysis',
      'Launch analytics, message optimization, and competitive intelligence',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'Italy Healthcare Coverage Footprint',
    bullets: [
      'Coverage across key regional healthcare systems and major clinical hubs',
      'Public-hospital and specialist-office representation for practical insight',
      'Cross-region analysis for heterogeneous implementation and uptake dynamics',
      'Integrated view from tertiary institutions to community-based pathways',
    ],
  },
  {
    id: 'compliance',
    title: 'Italy Compliance and Evidence Framework',
    bullets: [
      'AIFA-aware evidence strategy and reimbursement context support',
      'ICH-GCP standards and local ethics alignment',
      'GDPR-compliant data governance and security controls',
      'Structured quality validation for clinician and stakeholder samples',
    ],
  },
  {
    id: 'methodology',
    title: 'Italy Field Methodology',
    bullets: [
      'Specialty-targeted recruitment and credential validation',
      'Online, phone, and expert-interview deployment by objective',
      'Segmentation by region, setting, specialty, and access pathway',
      'Analytics for positioning, adoption barriers, and launch readiness',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in Italy',
    bullets: [
      'Oncology and specialty-care adoption pathways',
      'Cardiometabolic and chronic-care optimization opportunities',
      'Neurology, immunology, and rare disease access dynamics',
      'Comparator-sensitive positioning in high-priority therapeutic segments',
    ],
  },
];

const KUWAIT_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'Kuwait Pharmaceutical Market at a Glance',
    bullets: [
      'Market value: KWD 700 million (USD 2.3B), among the largest GCC medicine markets',
      'Growth rate: 7.8% CAGR (2024-2028) driven by chronic disease burden and healthcare investment',
      'Population: 4.9 million with a large expatriate segment and high per-capita healthcare spend',
      'Infrastructure: MOH hospitals, primary care clinics, specialized centers, and expanding private hospitals',
      'Dual system dynamic: national coverage via MOH and private-insurance-driven expatriate access',
    ],
    paragraphs: [
      'Kuwait is a high-value GCC market where access strategy must account for both public-sector procurement and private-sector adoption dynamics.',
      'Strong market execution requires aligned KFDA planning, MOH tender intelligence, and private-hospital stakeholder strategy.',
    ],
  },
  {
    id: 'regulatory-access',
    title: 'Regulatory and Market Access Landscape in Kuwait',
    bullets: [
      'Kuwait Food and Drug Authority pathways for medicine registration',
      'MOH formulary and Central Medical Stores tender dynamics shaping large-volume access',
      'Private hospital and insurance channels driving faster uptake for selected therapies',
      'GCC registration and expansion synergies for regional launch programs',
      'KFDA approval-to-formulary sequencing as a key commercialization lever',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive Kuwait Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across MOH and private healthcare settings',
      'KOL interviews and advisory boards across specialty and decision-making clusters',
      'KFDA and MOH-aligned market-access evidence support',
      'Tender intelligence and private formulary strategy insights',
      'Launch analytics, segmentation, and competitive intelligence',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'Kuwait Healthcare System Coverage',
    bullets: [
      'Capital, Hawalli, Farwaniya, Ahmadi, Jahra, and Mubarak Al-Kabeer coverage',
      'Major MOH hospitals and specialized centers across high-priority specialties',
      'Private hospital and clinic networks serving insured expatriate populations',
      'Cross-governorate recruitment and pathway mapping for actionable insight',
    ],
  },
  {
    id: 'compliance',
    title: 'Kuwait Compliance and Evidence Framework',
    bullets: [
      'KFDA and MOH-aware research planning and governance',
      'ICH-GCP standards and ethics-aligned execution protocols',
      'Arabic and English consent and fieldwork support',
      'GDPR-aligned data governance and enterprise security controls',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in Kuwait',
    bullets: [
      'Diabetes and cardiometabolic management',
      'Oncology and specialty access strategy',
      'Respiratory, nephrology, and gastroenterology pathways',
      'Neurology, hematology, rheumatology, and infectious disease priorities',
    ],
  },
];

const QATAR_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'Qatar Pharmaceutical Market at a Glance',
    bullets: [
      'Qatar is a high-value GCC pharmaceutical market with strong healthcare investment',
      'Growth is supported by population expansion, chronic disease burden, and innovation uptake',
      'Public and private channels require differentiated access and activation strategy',
      'Advanced specialist infrastructure supports evidence-based launch planning',
      'Commercial success depends on integrating access intelligence and field execution',
    ],
    paragraphs: [
      'Qatar rewards teams that align clinical value with practical stakeholder and institutional pathways.',
      'High-performing strategy connects evidence generation, market access, and local implementation discipline.',
    ],
  },
  {
    id: 'regulatory-access',
    title: 'Regulatory and Market Access Landscape in Qatar',
    bullets: [
      'Regulatory and formulary pathways shape adoption pace by channel',
      'Public procurement and institutional decision logic influence large-volume access',
      'Private-sector pathways can accelerate uptake in selected therapeutic categories',
      'Cross-GCC evidence planning improves regional launch efficiency',
      'Stakeholder sequencing is essential for predictable adoption outcomes',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive Qatar Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across public and private settings',
      'KOL interviews and expert advisory boards by therapeutic area',
      'Market-access evidence support for formulary and stakeholder decisions',
      'Tender and channel intelligence for launch optimization',
      'Competitive intelligence, segmentation, and adoption analytics',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'Qatar Healthcare System Coverage',
    bullets: [
      'Coverage across major healthcare institutions and specialist centers',
      'Public and private provider network representation',
      'Specialty-level recruitment in high-priority therapeutic segments',
      'Cross-channel pathway mapping for practical commercial planning',
    ],
  },
  {
    id: 'compliance',
    title: 'Qatar Compliance and Evidence Framework',
    bullets: [
      'Regulatory-aware evidence planning and governance',
      'ICH-GCP standards and ethics-aligned research execution',
      'Arabic and English fieldwork support',
      'GDPR-aligned data governance and enterprise-grade security',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in Qatar',
    bullets: [
      'Oncology and specialty-care access pathways',
      'Cardiometabolic and chronic-disease management',
      'Respiratory, neurology, and immunology priorities',
      'Rare disease and high-value therapy access dynamics',
    ],
  },
];

const BAHRAIN_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'Bahrain Pharmaceutical Market at a Glance',
    bullets: [
      'Bahrain is a strategically important GCC market with strong healthcare modernization',
      'Public-private channel balance shapes practical access and adoption dynamics',
      'Market growth is driven by chronic disease demand and specialist-care needs',
      'Institutional decision pathways require tailored stakeholder strategy',
      'Commercial outcomes improve with integrated evidence and execution planning',
    ],
    paragraphs: [
      'Bahrain rewards teams that combine local healthcare insight with disciplined launch and access planning.',
      'Effective strategy links physician behavior, formulary dynamics, and channel execution from day one.',
    ],
  },
  {
    id: 'regulatory-access',
    title: 'Regulatory and Market Access Landscape in Bahrain',
    bullets: [
      'Regulatory and reimbursement expectations shape launch sequencing',
      'Public-sector pathways influence broad access dynamics',
      'Private providers support faster adoption in selected therapy areas',
      'Cross-GCC market intelligence enhances portfolio planning',
      'Stakeholder mapping is critical for sustained uptake',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive Bahrain Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP research across key channels',
      'Qualitative KOL interviews and advisory-board programs',
      'Market-access evidence support for stakeholder and formulary strategy',
      'Channel intelligence and adoption-barrier analytics',
      'Competitive tracking and launch-readiness measurement',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'Bahrain Healthcare System Coverage',
    bullets: [
      'Coverage across major public hospitals and private provider networks',
      'Specialty-focused recruitment across key therapeutic segments',
      'Public and private pathway insight for practical execution',
      'Integrated stakeholder mapping for evidence-backed decision-making',
    ],
  },
  {
    id: 'compliance',
    title: 'Bahrain Compliance and Evidence Framework',
    bullets: [
      'Regulatory-aware evidence strategy and governance',
      'ICH-GCP standards and ethics-aligned execution',
      'Arabic and English research deployment capabilities',
      'GDPR-aligned data controls and secure infrastructure',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in Bahrain',
    bullets: [
      'Oncology and specialty treatment pathways',
      'Cardiometabolic and endocrine care priorities',
      'Respiratory, neurology, and immunology opportunity areas',
      'Rare disease access and high-value therapy strategy',
    ],
  },
];

const OMAN_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'Oman Pharmaceutical Market at a Glance',
    bullets: [
      'Oman is a growing GCC pharmaceutical market with expanding healthcare infrastructure',
      'Public and private systems require differentiated strategy and execution',
      'Chronic disease trends and specialty needs drive therapy demand',
      'Institutional decision processes shape adoption speed by segment',
      'Commercial performance improves when access and field strategy are tightly aligned',
    ],
    paragraphs: [
      'Oman rewards teams that combine local pathway intelligence with practical implementation planning.',
      'Successful market strategy integrates evidence, stakeholder sequencing, and channel-specific activation.',
    ],
  },
  {
    id: 'regulatory-access',
    title: 'Regulatory and Market Access Landscape in Oman',
    bullets: [
      'Regulatory and formulary pathways shape adoption and launch pacing',
      'Public-sector decision dynamics influence broad market penetration',
      'Private-sector channels provide targeted acceleration opportunities',
      'Cross-GCC intelligence improves sequencing and portfolio efficiency',
      'Stakeholder engagement planning is essential for durable access outcomes',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive Oman Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across public and private channels',
      'KOL interviews and specialty-level stakeholder intelligence',
      'Market-access evidence planning and channel strategy support',
      'Adoption analytics, segmentation, and barrier identification',
      'Competitive intelligence and launch-readiness optimization',
    ],
  },
  {
    id: 'geographic-coverage',
    title: 'Oman Healthcare System Coverage',
    bullets: [
      'Coverage across major health regions and institutional care settings',
      'Public-hospital and private-provider representation',
      'Specialty recruitment for priority therapeutic programs',
      'Cross-channel pathway mapping for execution-ready insight',
    ],
  },
  {
    id: 'compliance',
    title: 'Oman Compliance and Evidence Framework',
    bullets: [
      'Regulatory-aware evidence planning and governance',
      'ICH-GCP standards and ethics-aligned fieldwork',
      'Arabic and English research capability',
      'GDPR-aligned data governance and secure operations',
    ],
  },
  {
    id: 'therapeutic-areas',
    title: 'Priority Therapeutic Areas in Oman',
    bullets: [
      'Oncology and specialty-care adoption pathways',
      'Cardiometabolic and chronic-care strategy priorities',
      'Respiratory, neurology, and immunology therapeutic demand',
      'Rare disease and complex-care access planning',
    ],
  },
];

const EGYPT_SECTIONS: UaeSection[] = [
  {
    id: 'market-overview',
    title: 'Egypt Pharmaceutical Market at a Glance',
    bullets: [
      'Market value: EGP 75 billion (USD 2.5B) pharmaceutical market, largest in North Africa',
      'Growth rate: 12.3% CAGR (2024-2028) driven by UHI expansion and population growth',
      'Population: 105+ million with large, urbanizing care demand',
      'Healthcare infrastructure: 1,800+ MOH hospitals and units, 450+ university hospitals, 600+ private hospitals',
      'Diagnostics network: 2,500+ laboratories with major chain influence',
    ],
    paragraphs: [
      'Egypt is a scale healthcare market where physician behavior, institutional pathways, and access sequencing determine commercial outcomes.',
      'Execution-ready strategy must align EDA pathways, MOH dynamics, and real-world diagnostic and treatment behavior across key regions.',
    ],
  },
  {
    id: 'mena-hub',
    title: 'MENA Regional Hub Dynamics',
    bullets: [
      'Gateway position to North Africa and Levant markets',
      'Large physician base and robust academic medical infrastructure',
      'Arabic-language research capability transferable across MENA',
      'Local manufacturing and export ecosystem with strategic influence',
      'Regional intelligence value for multi-country launch planning',
    ],
  },
  {
    id: 'regulatory-access',
    title: 'Regulatory and Market Access Landscape in Egypt',
    bullets: [
      'Egyptian Drug Authority (EDA) as the central pharmaceutical regulator',
      'MOH formulary dynamics shaping large-scale public-sector access',
      'Universal Health Insurance rollout changing payer and provider behavior',
      'Reference pricing and local manufacturing incentives affecting commercialization',
      'EDA approval to formulary inclusion timelines requiring proactive sequencing',
    ],
  },
  {
    id: 'transformation',
    title: 'Egypt Healthcare Transformation Signals',
    bullets: [
      'Universal Health Insurance expansion toward broad population coverage',
      'Hospital modernization and infrastructure growth across key regions',
      'Diagnostics accreditation momentum and quality standardization',
      'Chronic disease burden driving sustained demand across multiple therapy areas',
      'Proven national-scale public-health execution capabilities',
    ],
  },
  {
    id: 'services',
    title: 'Comprehensive Egypt Pharmaceutical Market Research Services',
    bullets: [
      'Quantitative physician and HCP studies across MOH, university, and private systems',
      'Qualitative KOL interviews and pathway intelligence for key specialties',
      'EDA and market-access evidence support for launch and lifecycle decisions',
      'Diagnostic laboratory and testing-pathway insight programs',
      'Launch analytics, segmentation, and competitive intelligence',
    ],
  },
  {
    id: 'contact-next-steps',
    title: 'Cairo Office and Next Steps',
    bullets: [
      'BioNixus Egypt, 22 Beverly Hills, Sheikh Zayed, Al Jizah, Egypt',
      'Mobile: +20 120 688 2323',
      'Landline: +20 2 38576665',
      'Email: admin@bionixus.com',
      'Working hours: Sunday-Thursday, 9:00 AM - 5:30 PM EET',
    ],
  },
];

const GlobalWebsiteCountry = () => {
  const { countrySlug } = useParams<{ countrySlug: string }>();
  const { language } = useLanguage();
  const basePath = languagePaths[language] || '/';
  const country = countrySlug ? getCountryBySlug(countrySlug) : undefined;
  const countryName = country?.countryName ?? '';
  const regionName = country?.regionName ?? '';
  const regionKey = country?.regionKey ?? '';
  const slug = country?.slug ?? '';
  const genericFaq = useMemo(() => buildGenericFaq(countryName), [countryName]);
  const relatedCountries = useMemo(() => {
    if (!country) return [];
    return getCountryDirectory()
      .filter((item) => item.regionKey === regionKey && item.slug !== slug)
      .slice(0, 4);
  }, [country, regionKey, slug]);
  const marketSections = useMemo(
    () => buildMarketSections(countryName, regionName),
    [countryName, regionName]
  );
  const estimatedWordCount = useMemo(
    () => countWords(marketSections.map((s) => [s.title, ...s.paragraphs].join(' ')).join(' ')),
    [marketSections]
  );

  if (!country) {
    return (
      <>
        <Helmet>
          <title>Country Page Not Found | BioNixus</title>
          <meta name="prerender-status" content="404" />
          <meta name="robots" content="noindex" />
        </Helmet>
        <div className="min-h-screen bg-background" data-route-status="404">
          <Navbar />
          <main className="section-padding pt-24 pb-20">
            <div className="container-wide max-w-4xl mx-auto">
              <h1 className="text-3xl md:text-4xl font-display font-semibold text-foreground mb-4">
                Country page not found
              </h1>
              <p className="text-muted-foreground mb-8">
                The requested country page is not available. Browse all countries from the global websites hub.
              </p>
              <Link to="/global-websites" className="inline-flex items-center gap-2 text-primary font-medium hover:underline">
                <ArrowLeft className="w-4 h-4" /> Back to Global Websites
              </Link>
            </div>
          </main>
          <Footer />
        </div>
      </>
    );
  }

  const canonicalUrl = `https://www.bionixus.com/global-websites/${country.slug}`;
  const isUaePage = country.slug === 'united-arab-emirates';
  const isSaudiPage = country.slug === 'saudi-arabia';
  const isUsPage = country.slug === 'united-states';
  const isUkPage = country.slug === 'united-kingdom';
  const isGermanyPage = country.slug === 'germany';
  const isFrancePage = country.slug === 'france';
  const isSpainPage = country.slug === 'spain';
  const isItalyPage = country.slug === 'italy';
  const isKuwaitPage = country.slug === 'kuwait';
  const isQatarPage = country.slug === 'qatar';
  const isBahrainPage = country.slug === 'bahrain';
  const isOmanPage = country.slug === 'oman';
  const isEgyptPage = country.slug === 'egypt';

  return (
    <div className="min-h-screen bg-background">
      <Helmet>
        <title>
          {isUaePage
            ? 'UAE Pharmaceutical Market Research | Dubai and Abu Dhabi Healthcare Insights | BioNixus'
            : isSaudiPage
              ? 'Saudi Arabia Pharmaceutical Market Research | SFDA, NUPCO and Vision 2030 Intelligence | BioNixus'
              : isUsPage
                ? 'US Pharmaceutical Market Research | Physician Surveys, KOL Insights and Payer Intelligence | BioNixus'
                : isUkPage
                  ? 'UK Pharmaceutical Market Research | NHS, NICE and Private Healthcare Intelligence | BioNixus'
                  : isGermanyPage
                    ? 'Germany Pharmaceutical Market Research | AMNOG, HTA and Commercial Intelligence | BioNixus'
                    : isFrancePage
                      ? 'France Pharmaceutical Market Research | HAS, HTA and Commercial Intelligence | BioNixus'
                      : isSpainPage
                        ? 'Spain Pharmaceutical Market Research | HTA and Commercial Intelligence | BioNixus'
                        : isItalyPage
                          ? 'Italy Pharmaceutical Market Research | AIFA, HTA and Commercial Intelligence | BioNixus'
                        : isKuwaitPage
                          ? 'Kuwait Pharmaceutical Market Research | MOH, KFDA and Private Healthcare Intelligence | BioNixus'
                        : isQatarPage
                          ? 'Qatar Pharmaceutical Market Research | Public and Private Healthcare Intelligence | BioNixus'
                        : isBahrainPage
                          ? 'Bahrain Pharmaceutical Market Research | Public and Private Healthcare Intelligence | BioNixus'
                        : isOmanPage
                          ? 'Oman Pharmaceutical Market Research | Public and Private Healthcare Intelligence | BioNixus'
                        : isEgyptPage
                          ? 'Egypt Pharmaceutical Market Research | MOH, HCV Expertise and MENA Hub | BioNixus'
            : `${country.countryName} Pharmaceutical Market Research | Global Healthcare Intelligence | BioNixus`}
        </title>
        <meta
          name="description"
          content={
            isUaePage
              ? 'Leading UAE pharmaceutical market research services with physician surveys, KOL interviews, and market access intelligence across Dubai, Abu Dhabi, and Northern Emirates.'
              : isSaudiPage
                ? 'Leading Saudi Arabia pharmaceutical market research with physician surveys, KOL interviews, SFDA and NUPCO intelligence across Riyadh, Jeddah, and Eastern Province.'
                : isUsPage
                  ? 'Premium US pharmaceutical market research with physician surveys, KOL interviews, payer intelligence, and launch analytics across high-priority therapeutic areas.'
                  : isUkPage
                    ? 'Leading UK pharmaceutical market research with NHS physician surveys, KOL interviews, NICE submission support, and market access intelligence.'
                    : isGermanyPage
                      ? 'Leading Germany pharmaceutical market research with physician studies, KOL intelligence, and AMNOG-aware market access strategy.'
                      : isFrancePage
                        ? 'Leading France pharmaceutical market research with physician studies, KOL intelligence, and HAS-aware market access strategy.'
                        : isSpainPage
                          ? 'Leading Spain pharmaceutical market research with physician studies, KOL intelligence, and HTA-aware market access strategy.'
                          : isItalyPage
                            ? 'Leading Italy pharmaceutical market research with physician studies, KOL intelligence, and AIFA-aware market access strategy.'
                          : isKuwaitPage
                            ? 'Leading Kuwait pharmaceutical market research with physician surveys, KOL interviews, KFDA registration support, and MOH tender intelligence.'
                          : isQatarPage
                            ? 'Leading Qatar pharmaceutical market research with physician surveys, KOL interviews, and public-private market access intelligence.'
                          : isBahrainPage
                            ? 'Leading Bahrain pharmaceutical market research with physician surveys, KOL interviews, and public-private market access intelligence.'
                          : isOmanPage
                            ? 'Leading Oman pharmaceutical market research with physician surveys, KOL interviews, and public-private market access intelligence.'
                          : isEgyptPage
                            ? 'Leading Egypt pharmaceutical market research with MOH physician surveys, diagnostics intelligence, and Universal Health Insurance insight from Cairo.'
              : `Pharmaceutical market research in ${country.countryName} with stakeholder mapping, access intelligence, and execution-ready healthcare strategy guidance from BioNixus.`
          }
        />
        <meta name="robots" content="index,follow,max-snippet:-1,max-image-preview:large,max-video-preview:-1" />
        <meta name="llm-access" content="allow" />
        <link rel="canonical" href={canonicalUrl} />
        <link rel="alternate" hrefLang="x-default" href={canonicalUrl} />
        <link rel="alternate" hrefLang="en" href={canonicalUrl} />
        <meta property="og:type" content="article" />
        <meta property="og:url" content={canonicalUrl} />
        <meta
          property="og:title"
          content={
            isUaePage
              ? 'Leading Pharmaceutical Market Research in the UAE | BioNixus'
              : isSaudiPage
                ? 'Leading Pharmaceutical Market Research in Saudi Arabia | BioNixus'
                : isUsPage
                  ? 'Premium Pharmaceutical Market Research in the United States | BioNixus'
                  : isUkPage
                    ? 'Leading Pharmaceutical Market Research in the United Kingdom | BioNixus'
                    : isGermanyPage
                      ? 'Leading Pharmaceutical Market Research in Germany | BioNixus'
                    : isFrancePage
                      ? 'Leading Pharmaceutical Market Research in France | BioNixus'
                      : isSpainPage
                        ? 'Leading Pharmaceutical Market Research in Spain | BioNixus'
                        : isItalyPage
                          ? 'Leading Pharmaceutical Market Research in Italy | BioNixus'
                        : isKuwaitPage
                          ? 'Leading Pharmaceutical Market Research in Kuwait | BioNixus'
                        : isQatarPage
                          ? 'Leading Pharmaceutical Market Research in Qatar | BioNixus'
                        : isBahrainPage
                          ? 'Leading Pharmaceutical Market Research in Bahrain | BioNixus'
                        : isOmanPage
                          ? 'Leading Pharmaceutical Market Research in Oman | BioNixus'
                        : isEgyptPage
                          ? 'Leading Pharmaceutical Market Research in Egypt | BioNixus'
              : `${country.countryName} Pharmaceutical Market Research | BioNixus`
          }
        />
        <meta
          property="og:description"
          content={
            isUaePage
              ? 'Dubai and Abu Dhabi healthcare intelligence for drug development, market access, and commercialization in the Emirates.'
              : isSaudiPage
                ? 'Vision 2030-aligned healthcare intelligence for SFDA registration, NUPCO strategy, and pharmaceutical market access in Saudi Arabia.'
                : isUsPage
                  ? 'Physician-first intelligence for US drug development, launch readiness, payer engagement, and commercial strategy in a complex access environment.'
                  : isUkPage
                    ? 'NHS and private healthcare intelligence for drug development, NICE submissions, and commercial strategy across the United Kingdom.'
                    : isGermanyPage
                      ? 'Market intelligence for Germany pharmaceutical strategy, including physician behavior, AMNOG context, and launch execution planning.'
                      : isFrancePage
                        ? 'Market intelligence for France pharmaceutical strategy, including clinician behavior, HTA context, and launch execution planning.'
                        : isSpainPage
                          ? 'Market intelligence for Spain pharmaceutical strategy, including clinician behavior, HTA context, and launch execution planning.'
                          : isItalyPage
                            ? 'Market intelligence for Italy pharmaceutical strategy, including clinician behavior, AIFA context, and launch execution planning.'
                          : isKuwaitPage
                            ? 'Market intelligence for Kuwait pharmaceutical strategy, including MOH pathways, private-sector dynamics, and GCC-oriented launch execution planning.'
                          : isQatarPage
                            ? 'Market intelligence for Qatar pharmaceutical strategy, including public-private healthcare dynamics and GCC-oriented launch execution planning.'
                          : isBahrainPage
                            ? 'Market intelligence for Bahrain pharmaceutical strategy, including public-private healthcare dynamics and GCC-oriented launch execution planning.'
                          : isOmanPage
                            ? 'Market intelligence for Oman pharmaceutical strategy, including public-private healthcare dynamics and GCC-oriented launch execution planning.'
                          : isEgyptPage
                            ? 'Market intelligence for Egypt pharmaceutical strategy, including MOH pathways, diagnostics behavior, and MENA-relevant launch execution planning.'
              : `Country-specific healthcare market strategy and pharmaceutical intelligence for ${country.countryName}.`
          }
        />
        <script type="application/ld+json">
          {JSON.stringify({
            '@context': 'https://schema.org',
            '@type': 'WebPage',
            name: `${country.countryName} Pharmaceutical Market Research`,
            url: canonicalUrl,
            description: `Country-specific healthcare market strategy and pharmaceutical intelligence for ${country.countryName}.`,
            inLanguage: 'en',
            isPartOf: {
              '@type': 'WebSite',
              name: 'BioNixus',
              url: 'https://www.bionixus.com',
            },
          })}
        </script>
        <script type="application/ld+json">
          {JSON.stringify({
            '@context': 'https://schema.org',
            '@type': 'Service',
            name: `Pharmaceutical Market Research in ${country.countryName}`,
            serviceType: 'Pharmaceutical Market Research',
            areaServed: {
              '@type': 'Country',
              name: country.countryName,
            },
            provider: {
              '@type': 'Organization',
              name: 'BioNixus',
              url: 'https://www.bionixus.com',
            },
          })}
        </script>
        {!isUaePage && !isSaudiPage && !isUsPage && !isUkPage && !isGermanyPage && !isFrancePage && !isSpainPage && !isItalyPage && !isKuwaitPage && !isQatarPage && !isBahrainPage && !isOmanPage && !isEgyptPage ? (
          <script type="application/ld+json">
            {JSON.stringify({
              '@context': 'https://schema.org',
              '@type': 'FAQPage',
              mainEntity: genericFaq.map((item) => ({
                '@type': 'Question',
                name: item.question,
                acceptedAnswer: { '@type': 'Answer', text: item.answer },
              })),
            })}
          </script>
        ) : null}
        {isUaePage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus UAE - Pharmaceutical Market Research',
                url: canonicalUrl,
                telephone: '+971-4-XXX-XXXX',
                areaServed: ['Dubai', 'Abu Dhabi', 'Sharjah', 'United Arab Emirates'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  streetAddress: 'Unit 2406, Swiss Tower, Cluster Y, JLT',
                  addressLocality: 'Dubai',
                  addressCountry: 'AE',
                },
                geo: {
                  '@type': 'GeoCoordinates',
                  latitude: 25.0657,
                  longitude: 55.141,
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: UAE_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isSaudiPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus Saudi Arabia - Pharmaceutical Market Research',
                url: canonicalUrl,
                telephone: '+966-12-XXX-XXXX',
                areaServed: ['Riyadh', 'Jeddah', 'Dammam', 'Saudi Arabia'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  streetAddress: 'Al Andalus District',
                  addressLocality: 'Jeddah',
                  addressCountry: 'SA',
                },
                geo: {
                  '@type': 'GeoCoordinates',
                  latitude: 21.5433,
                  longitude: 39.1728,
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: SAUDI_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isUsPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus United States - Pharmaceutical Market Research',
                url: canonicalUrl,
                telephone: '+1-888-465-5557',
                areaServed: ['United States'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  streetAddress: '30 N Gould St, Suite R',
                  addressLocality: 'Sheridan',
                  addressRegion: 'WY',
                  postalCode: '82801',
                  addressCountry: 'US',
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: US_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isUkPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus UK - Pharmaceutical Market Research',
                url: canonicalUrl,
                telephone: '+44-7727-666682',
                areaServed: ['England', 'Scotland', 'Wales', 'Northern Ireland', 'United Kingdom'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  streetAddress: '128 City Road',
                  addressLocality: 'London',
                  addressRegion: 'England',
                  postalCode: 'EC1V 2NX',
                  addressCountry: 'GB',
                },
                geo: {
                  '@type': 'GeoCoordinates',
                  latitude: 51.5272,
                  longitude: -0.0875,
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: UK_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isGermanyPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus Germany - Pharmaceutical Market Research',
                url: canonicalUrl,
                areaServed: ['Germany'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  addressCountry: 'DE',
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: GERMANY_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isFrancePage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus France - Pharmaceutical Market Research',
                url: canonicalUrl,
                areaServed: ['France'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  addressCountry: 'FR',
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: FRANCE_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isSpainPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus Spain - Pharmaceutical Market Research',
                url: canonicalUrl,
                areaServed: ['Spain'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  addressCountry: 'ES',
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: SPAIN_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isItalyPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus Italy - Pharmaceutical Market Research',
                url: canonicalUrl,
                areaServed: ['Italy'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  addressCountry: 'IT',
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: ITALY_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isKuwaitPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus Kuwait - Pharmaceutical Market Research',
                url: canonicalUrl,
                telephone: '+44-7727-666682',
                areaServed: ['Kuwait'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  addressCountry: 'KW',
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: KUWAIT_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isQatarPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus Qatar - Pharmaceutical Market Research',
                url: canonicalUrl,
                telephone: '+44-7727-666682',
                areaServed: ['Qatar'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  addressCountry: 'QA',
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: QATAR_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isBahrainPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus Bahrain - Pharmaceutical Market Research',
                url: canonicalUrl,
                telephone: '+44-7727-666682',
                areaServed: ['Bahrain'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  addressCountry: 'BH',
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: BAHRAIN_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isOmanPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus Oman - Pharmaceutical Market Research',
                url: canonicalUrl,
                telephone: '+44-7727-666682',
                areaServed: ['Oman'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  addressCountry: 'OM',
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: OMAN_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
        {isEgyptPage ? (
          <>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'ProfessionalService',
                name: 'BioNixus Egypt - Pharmaceutical Market Research',
                url: canonicalUrl,
                telephone: '+20-120-688-2323',
                areaServed: ['Cairo', 'Alexandria', 'Egypt', 'MENA'],
                serviceType: 'Pharmaceutical Market Research',
                address: {
                  '@type': 'PostalAddress',
                  streetAddress: '22 Beverly Hills, Sheikh Zayed',
                  addressLocality: 'Al Jizah',
                  addressCountry: 'EG',
                },
                geo: {
                  '@type': 'GeoCoordinates',
                  latitude: 30.0131,
                  longitude: 30.976,
                },
              })}
            </script>
            <script type="application/ld+json">
              {JSON.stringify({
                '@context': 'https://schema.org',
                '@type': 'FAQPage',
                mainEntity: EGYPT_FAQS.map((item) => ({
                  '@type': 'Question',
                  name: item.question,
                  acceptedAnswer: { '@type': 'Answer', text: item.answer },
                })),
              })}
            </script>
          </>
        ) : null}
      </Helmet>

      <Navbar />

      <main>
        <section className="section-padding pt-24 pb-6">
          <div className="container-wide max-w-5xl mx-auto">
            <Link
              to="/global-websites"
              className="inline-flex items-center gap-2 text-primary font-medium hover:underline mb-6"
            >
              <ArrowLeft className="w-4 h-4" /> Back to Global Websites
            </Link>
            <h1 className="text-3xl md:text-4xl lg:text-5xl font-display font-semibold text-foreground mb-4">
              {isUaePage
                ? 'Leading Pharmaceutical Market Research in the UAE'
                : isSaudiPage
                  ? 'Leading Pharmaceutical Market Research in Saudi Arabia'
                  : isUsPage
                    ? 'Premium Pharmaceutical Market Research in the United States'
                    : isUkPage
                      ? 'Leading Pharmaceutical Market Research in the United Kingdom'
                      : isGermanyPage
                        ? 'Leading Pharmaceutical Market Research in Germany'
                        : isFrancePage
                          ? 'Leading Pharmaceutical Market Research in France'
                          : isSpainPage
                            ? 'Leading Pharmaceutical Market Research in Spain'
                            : isItalyPage
                              ? 'Leading Pharmaceutical Market Research in Italy'
                            : isKuwaitPage
                              ? 'Leading Pharmaceutical Market Research in Kuwait'
                            : isQatarPage
                              ? 'Leading Pharmaceutical Market Research in Qatar'
                            : isBahrainPage
                              ? 'Leading Pharmaceutical Market Research in Bahrain'
                            : isOmanPage
                              ? 'Leading Pharmaceutical Market Research in Oman'
                            : isEgyptPage
                              ? 'Leading Pharmaceutical Market Research in Egypt'
                  : `${country.countryName} Healthcare Market Strategy`}
            </h1>
            {isKuwaitPage ? (
              <h2 className="text-xl md:text-2xl font-display font-medium text-foreground/90 mb-4">
                MOH Healthcare Intelligence, Private Sector Insights and GCC Market Access Strategy
              </h2>
            ) : isQatarPage ? (
              <h2 className="text-xl md:text-2xl font-display font-medium text-foreground/90 mb-4">
                Public and Private Healthcare Intelligence with GCC Market Access Strategy
              </h2>
            ) : isBahrainPage ? (
              <h2 className="text-xl md:text-2xl font-display font-medium text-foreground/90 mb-4">
                Public and Private Healthcare Intelligence with GCC Commercial Strategy Support
              </h2>
            ) : isOmanPage ? (
              <h2 className="text-xl md:text-2xl font-display font-medium text-foreground/90 mb-4">
                Public and Private Healthcare Intelligence with GCC Launch and Access Strategy
              </h2>
            ) : isEgyptPage ? (
              <h2 className="text-xl md:text-2xl font-display font-medium text-foreground/90 mb-4">
                MENA Regional Hub for MOH Healthcare Intelligence, HCV Expertise and Clinical Diagnostics
              </h2>
            ) : null}
            <p className="text-lg text-muted-foreground leading-relaxed max-w-3xl">
              {isUaePage
                ? 'Dubai and Abu Dhabi healthcare intelligence for drug development and market access. We deliver quantitative and qualitative research converting clinical perspectives into commercial strategy across the Emirates.'
                : isSaudiPage
                  ? 'Vision 2030-aligned healthcare intelligence for SFDA registration and market access. We transform physician, hospital, and payer insights into execution-ready commercial strategy across the Kingdom.'
                  : isUsPage
                    ? 'Physician-first intelligence for drug development, launch readiness, and commercial strategy across the US healthcare system, from academic centers to community practice networks.'
                    : isUkPage
                      ? 'NHS and private healthcare intelligence for drug development, NICE submissions, and commercial strategy across England, Scotland, Wales, and Northern Ireland.'
                      : isGermanyPage
                        ? 'AMNOG-aware pharmaceutical market intelligence for Germany with physician, stakeholder, and access insights across key specialty pathways.'
                        : isFrancePage
                          ? 'HAS-aware pharmaceutical market intelligence for France with clinician, stakeholder, and access insights across key specialty pathways.'
                          : isSpainPage
                            ? 'HTA-aware pharmaceutical market intelligence for Spain with clinician, stakeholder, and access insights across key specialty pathways.'
                            : isItalyPage
                              ? 'AIFA-aware pharmaceutical market intelligence for Italy with clinician, stakeholder, and access insights across key specialty pathways.'
                            : isKuwaitPage
                              ? 'Comprehensive quantitative and qualitative research across Kuwait\'s dual healthcare system, from MOH hospitals to private groups and specialty clinics.'
                            : isQatarPage
                              ? 'Comprehensive quantitative and qualitative research across Qatar\'s public and private healthcare system, from major hospitals to specialty centers and private clinics.'
                            : isBahrainPage
                              ? 'Comprehensive quantitative and qualitative research across Bahrain\'s public and private healthcare system, transforming clinical insight into commercial strategy.'
                            : isOmanPage
                              ? 'Comprehensive quantitative and qualitative research across Oman\'s public and private healthcare system, turning clinical insight into access-ready commercial strategy.'
                            : isEgyptPage
                              ? 'Comprehensive quantitative and qualitative research across Egypt\'s transforming healthcare landscape, from MOH hospitals to university medical centers and diagnostics networks.'
                : `A standardized long-form market blueprint for ${country.countryName} within our ${country.regionName} coverage. This page follows the same structure used across all global market pages for consistency in planning, execution, and leadership comparison.`}
            </p>
            {isUaePage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by teams operating in Dubai Healthcare City, SEHA network, Abu Dhabi, Sharjah, and Northern Emirates.
              </p>
            ) : isSaudiPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by pharmaceutical teams across Riyadh, Jeddah, Eastern Province, and major Saudi medical networks.
              </p>
            ) : isUsPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Serving teams across academic medical centers, integrated delivery networks, specialty groups, and payer-influenced channels in the US.
              </p>
            ) : isUkPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by teams working across NHS systems, private hospital groups, and UK academic medical centres.
              </p>
            ) : isGermanyPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by teams working across German university hospitals, ambulatory specialist networks, and high-priority therapeutic markets.
              </p>
            ) : isFrancePage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by teams working across French university hospitals, regional systems, and priority specialty markets.
              </p>
            ) : isSpainPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by teams working across Spanish hospital systems, regional networks, and high-priority therapeutic markets.
              </p>
            ) : isItalyPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by teams working across Italian regional health systems, university hospitals, and priority specialty markets.
              </p>
            ) : isKuwaitPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by pharmaceutical companies operating in Jaber Al-Ahmad Hospital, Mubarak Al-Kabeer Hospital, Hadi Clinic, Al-Salam Hospital, Dar Al Shifa Hospital, Taiba Hospital, and Kuwait Cancer Control Center.
              </p>
            ) : isQatarPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by teams working across Qatar public hospitals, private provider networks, and high-priority specialty programs.
              </p>
            ) : isBahrainPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by teams working across Bahrain government hospitals, private healthcare groups, and specialty-focused therapeutic markets.
              </p>
            ) : isOmanPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by teams working across Oman public hospitals, private providers, and strategic specialty-care pathways.
              </p>
            ) : isEgyptPage ? (
              <p className="text-sm text-muted-foreground mt-4">
                Trusted by pharmaceutical companies operating in Cairo University Hospitals, Ain Shams University Hospitals, MOH Central Hospitals, National Cancer Institute, Liver Institute Menoufia, Alborg Labs, Almokhtabar, and Alfa Lab.
              </p>
            ) : (
              <p className="text-sm text-muted-foreground mt-4">
                Estimated page length: ~{estimatedWordCount.toLocaleString()} words
              </p>
            )}
            {isKuwaitPage ? (
              <>
                <p className="text-sm text-muted-foreground mt-4">
                  Explore our broader strategy framework in the{' '}
                  <Link to="/healthcare-market-research" className="text-primary hover:underline">
                    healthcare market research hub
                  </Link>
                  .
                </p>
                <div className="mt-5 grid sm:grid-cols-2 gap-3 max-w-2xl">
                  <Link
                    to="/contact"
                    className="inline-flex items-center justify-center gap-2 px-5 py-3 rounded-xl bg-primary text-primary-foreground font-semibold hover:bg-primary/90 transition-colors"
                  >
                    Request Kuwait Market Proposal
                    <ArrowRight className="w-4 h-4" />
                  </Link>
                  <Link
                    to="/insights"
                    className="inline-flex items-center justify-center gap-2 px-5 py-3 rounded-xl border border-border bg-card text-foreground font-semibold hover:bg-muted transition-colors"
                  >
                    Download Kuwait Pharma Report 2025
                    <ArrowRight className="w-4 h-4" />
                  </Link>
                </div>
              </>
            ) : isQatarPage ? (
              <>
                <p className="text-sm text-muted-foreground mt-4">
                  Explore our broader strategy framework in the{' '}
                  <Link to="/healthcare-market-research" className="text-primary hover:underline">
                    healthcare market research hub
                  </Link>
                  .
                </p>
                <div className="mt-5 grid sm:grid-cols-2 gap-3 max-w-2xl">
                  <Link
                    to="/contact"
                    className="inline-flex items-center justify-center gap-2 px-5 py-3 rounded-xl bg-primary text-primary-foreground font-semibold hover:bg-primary/90 transition-colors"
                  >
                    Request Qatar Market Proposal
                    <ArrowRight className="w-4 h-4" />
                  </Link>
                  <Link
                    to="/insights"
                    className="inline-flex items-center justify-center gap-2 px-5 py-3 rounded-xl border border-border bg-card text-foreground font-semibold hover:bg-muted transition-colors"
                  >
                    Download Qatar Pharma Report 2025
                    <ArrowRight className="w-4 h-4" />
                  </Link>
                </div>
              </>
            ) : isBahrainPage ? (
              <>
                <p className="text-sm text-muted-foreground mt-4">
                  Explore our broader strategy framework in the{' '}
                  <Link to="/healthcare-market-research" className="text-primary hover:underline">
                    healthcare market research hub
                  </Link>
                  .
                </p>
                <div className="mt-5 grid sm:grid-cols-2 gap-3 max-w-2xl">
                  <Link
                    to="/contact"
                    className="inline-flex items-center justify-center gap-2 px-5 py-3 rounded-xl bg-primary text-primary-foreground font-semibold hover:bg-primary/90 transition-colors"
                  >
                    Request Bahrain Market Proposal
                    <ArrowRight className="w-4 h-4" />
                  </Link>
                  <Link
                    to="/insights"
                    className="inline-flex items-center justify-center gap-2 px-5 py-3 rounded-xl border border-border bg-card text-foreground font-semibold hover:bg-muted transition-colors"
                  >
                    Download Bahrain Pharma Report 2025
                    <ArrowRight className="w-4 h-4" />
                  </Link>
                </div>
              </>
            ) : isOmanPage ? (
              <>
                <p className="text-sm text-muted-foreground mt-4">
                  Explore our broader strategy framework in the{' '}
                  <Link to="/healthcare-market-research" className="text-primary hover:underline">
                    healthcare market research hub
                  </Link>
                  .
                </p>
                <div className="mt-5 grid sm:grid-cols-2 gap-3 max-w-2xl">
                  <Link
                    to="/contact"
                    className="inline-flex items-center justify-center gap-2 px-5 py-3 rounded-xl bg-primary text-primary-foreground font-semibold hover:bg-primary/90 transition-colors"
                  >
                    Request Oman Market Proposal
                    <ArrowRight className="w-4 h-4" />
                  </Link>
                  <Link
                    to="/insights"
                    className="inline-flex items-center justify-center gap-2 px-5 py-3 rounded-xl border border-border bg-card text-foreground font-semibold hover:bg-muted transition-colors"
                  >
                    Download Oman Pharma Report 2025
                    <ArrowRight className="w-4 h-4" />
                  </Link>
                </div>
              </>
            ) : isEgyptPage ? (
              <>
                <p className="text-sm text-muted-foreground mt-4">
                  Explore our broader strategy framework in the{' '}
                  <Link to="/healthcare-market-research" className="text-primary hover:underline">
                    healthcare market research hub
                  </Link>
                  .
                </p>
                <div className="mt-5 grid sm:grid-cols-2 gap-3 max-w-2xl">
                  <Link
                    to="/contact"
                    className="inline-flex items-center justify-center gap-2 px-5 py-3 rounded-xl bg-primary text-primary-foreground font-semibold hover:bg-primary/90 transition-colors"
                  >
                    Request Egypt Market Proposal
                    <ArrowRight className="w-4 h-4" />
                  </Link>
                  <Link
                    to="/insights"
                    className="inline-flex items-center justify-center gap-2 px-5 py-3 rounded-xl border border-border bg-card text-foreground font-semibold hover:bg-muted transition-colors"
                  >
                    Download Egypt Pharma Report 2025
                    <ArrowRight className="w-4 h-4" />
                  </Link>
                </div>
              </>
            ) : null}
          </div>
        </section>

        <section className="section-padding py-8">
          <div className="container-wide max-w-5xl mx-auto grid md:grid-cols-2 gap-6">
            <div className="bg-card border border-border rounded-xl p-6">
              <h2 className="text-xl font-display font-semibold text-foreground mb-3">Country details</h2>
              <p className="text-muted-foreground mb-2">
                <strong className="text-foreground">Country:</strong> {country.countryName}
              </p>
              <p className="text-muted-foreground mb-2">
                <strong className="text-foreground">Region:</strong> {country.regionName}
              </p>
              <p className="text-muted-foreground">
                <strong className="text-foreground">Languages:</strong> {formatLanguages(country.languages)}
              </p>
            </div>

            <div className="bg-card border border-border rounded-xl p-6">
              {isKuwaitPage || isQatarPage || isBahrainPage || isOmanPage ? (
                <>
                  <h2 className="text-xl font-display font-semibold text-foreground mb-3">
                    {isKuwaitPage ? 'Kuwait Contact' : isQatarPage ? 'Qatar Contact' : isBahrainPage ? 'Bahrain Contact' : 'Oman Contact'}
                  </h2>
                  <p className="text-muted-foreground">
                    {isKuwaitPage ? 'BioNixus - Kuwait Operations' : isQatarPage ? 'BioNixus - Qatar Operations' : isBahrainPage ? 'BioNixus - Bahrain Operations' : 'BioNixus - Oman Operations'}
                  </p>
                  <p className="text-muted-foreground">(Coordinated from UK office)</p>
                  <p className="text-muted-foreground mt-2">
                    <a href="tel:+447727666682" className="text-primary hover:underline">+44 7727 666682</a>
                  </p>
                  <p className="text-muted-foreground">
                    <a href="mailto:admin@bionixus.com" className="text-primary hover:underline">admin@bionixus.com</a>
                  </p>
                  <p className="text-muted-foreground mt-2">Sunday-Thursday, 9:00 AM - 5:00 PM AST</p>
                </>
              ) : isEgyptPage ? (
                <>
                  <h2 className="text-xl font-display font-semibold text-foreground mb-3">Cairo Office</h2>
                  <p className="text-muted-foreground">BioNixus Egypt</p>
                  <p className="text-muted-foreground">22 Beverly Hills, Sheikh Zayed, Al Jizah, Egypt</p>
                  <p className="text-muted-foreground mt-2">
                    <a href="tel:+201206882323" className="text-primary hover:underline">+20 120 688 2323</a> |{' '}
                    <a href="tel:+20238576665" className="text-primary hover:underline">+20 2 38576665</a>
                  </p>
                  <p className="text-muted-foreground">
                    <a href="mailto:admin@bionixus.com" className="text-primary hover:underline">admin@bionixus.com</a>
                  </p>
                  <p className="text-muted-foreground mt-2">Sunday-Thursday, 9:00 AM - 5:30 PM EET</p>
                </>
              ) : (
                <>
                  <h2 className="text-xl font-display font-semibold text-foreground mb-3">Market website</h2>
                  <a
                    href={country.url}
                    className="inline-flex items-center gap-2 text-primary font-medium hover:underline"
                  >
                    Visit primary route for {country.countryName}
                    <ExternalLink className="w-4 h-4" />
                  </a>
                </>
              )}
            </div>
          </div>
        </section>

        {isUaePage || isSaudiPage || isUsPage || isUkPage || isGermanyPage || isFrancePage || isSpainPage || isItalyPage || isKuwaitPage || isQatarPage || isBahrainPage || isOmanPage || isEgyptPage ? (
          <>
            <section className="section-padding py-8 bg-muted/30">
              <div className="container-wide max-w-5xl mx-auto">
                <h2 className="text-2xl font-display font-semibold text-foreground mb-5">
                  {isUaePage
                    ? 'UAE Trust and Compliance Highlights'
                    : isSaudiPage
                      ? 'Saudi Trust and Compliance Highlights'
                      : isUsPage
                        ? 'US Trust and Compliance Highlights'
                        : isUkPage
                          ? 'UK Trust and Compliance Highlights'
                          : isGermanyPage
                            ? 'Germany Trust and Compliance Highlights'
                            : isFrancePage
                              ? 'France Trust and Compliance Highlights'
                              : isSpainPage
                                ? 'Spain Trust and Compliance Highlights'
                                : isItalyPage
                                  ? 'Italy Trust and Compliance Highlights'
                                : isKuwaitPage
                                  ? 'Kuwait Trust and Compliance Highlights'
                                : isQatarPage
                                  ? 'Qatar Trust and Compliance Highlights'
                                : isBahrainPage
                                  ? 'Bahrain Trust and Compliance Highlights'
                                : isOmanPage
                                  ? 'Oman Trust and Compliance Highlights'
                                : 'Egypt Trust and Compliance Highlights'}
                </h2>
                <div className="grid sm:grid-cols-2 lg:grid-cols-5 gap-3">
                  {(isUaePage
                    ? ['DHA Compliant', 'MOHAP Aligned', 'HAAD Recognized', 'ICH-GCP Standards', 'GDPR Compliant']
                    : isSaudiPage
                      ? ['SFDA Compliant', 'MOH Aligned', 'Vision 2030 Partner', 'ICH-GCP Standards', 'GDPR Compliant']
                      : isUsPage
                        ? ['FDA Regulatory Intelligence', 'HIPAA Compliant', 'ICH-GCP Standards', 'AAHRPP IRB Partners', 'GDPR Compliant']
                        : isUkPage
                          ? ['MHRA Compliant', 'NICE Aligned', 'NHS REC Standards', 'ICH-GCP Certified', 'GDPR Compliant']
                          : isGermanyPage
                            ? ['AMNOG Aware', 'G-BA Context', 'GDPR Compliant', 'ICH-GCP Standards', 'HTA Ready']
                            : isFrancePage
                              ? ['HAS Aligned', 'HTA Ready', 'GDPR Compliant', 'ICH-GCP Standards', 'Pricing Context Aware']
                              : isSpainPage
                                ? ['HTA Ready', 'Regional Access Aware', 'GDPR Compliant', 'ICH-GCP Standards', 'Pricing Context Aware']
                                : isItalyPage
                                  ? ['AIFA Aligned', 'Regional Access Ready', 'GDPR Compliant', 'ICH-GCP Standards', 'HTA Ready']
                                : isKuwaitPage
                                  ? ['KFDA Compliant', 'MOH Aligned', 'GCC Health Council Recognition', 'ICH-GCP Standards', 'GDPR Compliant']
                                : isQatarPage
                                  ? ['MOPH Aligned', 'Public-Private Access Ready', 'GCC Health Council Recognition', 'ICH-GCP Standards', 'GDPR Compliant']
                                : isBahrainPage
                                  ? ['NHRA Aware', 'Public-Private Access Ready', 'GCC Health Council Recognition', 'ICH-GCP Standards', 'GDPR Compliant']
                                : isOmanPage
                                  ? ['MOH Aligned', 'Public-Private Access Ready', 'GCC Health Council Recognition', 'ICH-GCP Standards', 'GDPR Compliant']
                                : ['EDA Compliant', 'MOH Aligned', 'Universal Health Insurance Integration', 'ICH-GCP Standards', 'GDPR Compliant']).map((item) => (
                    <div key={item} className="bg-card border border-border rounded-lg px-4 py-3 text-sm font-medium text-foreground">
                      {item}
                    </div>
                  ))}
                </div>
              </div>
            </section>

            <section className="section-padding py-10">
              <div className="container-wide max-w-5xl mx-auto space-y-8">
                {(isUaePage ? UAE_SECTIONS : isSaudiPage ? SAUDI_SECTIONS : isUsPage ? US_SECTIONS : isUkPage ? UK_SECTIONS : isGermanyPage ? GERMANY_SECTIONS : isFrancePage ? FRANCE_SECTIONS : isSpainPage ? SPAIN_SECTIONS : isItalyPage ? ITALY_SECTIONS : isKuwaitPage ? KUWAIT_SECTIONS : isQatarPage ? QATAR_SECTIONS : isBahrainPage ? BAHRAIN_SECTIONS : isOmanPage ? OMAN_SECTIONS : EGYPT_SECTIONS).map((section) => (
                  <article key={section.id} id={section.id} className="bg-card border border-border rounded-xl p-6 md:p-8">
                    <h2 className="text-2xl font-display font-semibold text-foreground mb-4">{section.title}</h2>
                    {section.paragraphs ? (
                      <div className="space-y-3 text-muted-foreground leading-relaxed mb-4">
                        {section.paragraphs.map((paragraph) => (
                          <p key={`${section.id}-${paragraph.slice(0, 24)}`}>{paragraph}</p>
                        ))}
                      </div>
                    ) : null}
                    {section.bullets ? (
                      <ul className="list-disc pl-5 space-y-2 text-muted-foreground leading-relaxed">
                        {section.bullets.map((bullet) => (
                          <li key={`${section.id}-${bullet.slice(0, 24)}`}>{bullet}</li>
                        ))}
                      </ul>
                    ) : null}
                  </article>
                ))}

                <article id="case-studies" className="bg-card border border-border rounded-xl p-6 md:p-8">
                  <h2 className="text-2xl font-display font-semibold text-foreground mb-4">
                    {isUaePage
                      ? 'UAE Market Research Success Stories'
                      : isSaudiPage
                        ? 'Saudi Arabia Market Research Success Stories'
                        : isUsPage
                          ? 'United States Market Research Success Stories'
                          : isUkPage
                            ? 'United Kingdom Market Research Success Stories'
                            : isGermanyPage
                              ? 'Germany Market Research Success Stories'
                              : isFrancePage
                                ? 'France Market Research Success Stories'
                                : isSpainPage
                                  ? 'Spain Market Research Success Stories'
                                  : isItalyPage
                                    ? 'Italy Market Research Success Stories'
                                  : isKuwaitPage
                                    ? 'Kuwait Market Research Success Stories'
                                : isQatarPage
                                  ? 'Qatar Market Research Success Stories'
                                : isBahrainPage
                                  ? 'Bahrain Market Research Success Stories'
                                : isOmanPage
                                  ? 'Oman Market Research Success Stories'
                                  : 'Egypt Market Research Success Stories'}
                  </h2>
                  <div className="space-y-6 text-muted-foreground leading-relaxed">
                    <div>
                      <h3 className="text-lg font-semibold text-foreground mb-2">
                        {isUaePage
                          ? 'Case Study 1: Oncology Launch Readiness'
                          : isSaudiPage
                            ? 'Case Study 1: Oncology Biosimilar Tender Strategy'
                            : isUsPage
                              ? 'Case Study 1: US Oncology Launch Readiness'
                              : isUkPage
                                ? 'Case Study 1: NICE Oncology Appraisal Evidence Strategy'
                                : isGermanyPage
                                  ? 'Case Study 1: Germany Oncology Launch and Access Strategy'
                                  : isFrancePage
                                    ? 'Case Study 1: France Oncology Launch and Access Strategy'
                                    : isSpainPage
                                      ? 'Case Study 1: Spain Oncology Launch and Access Strategy'
                                      : isItalyPage
                                        ? 'Case Study 1: Italy Oncology Launch and Access Strategy'
                                      : isKuwaitPage
                                        ? 'Case Study 1: Kuwait MOH Oncology Access Strategy'
                                    : isQatarPage
                                      ? 'Case Study 1: Qatar Oncology Access and Stakeholder Strategy'
                                    : isBahrainPage
                                      ? 'Case Study 1: Bahrain Oncology Launch Readiness Strategy'
                                    : isOmanPage
                                      ? 'Case Study 1: Oman Oncology Access and Adoption Strategy'
                                      : 'Case Study 1: Egypt MOH Oncology Access Strategy'}
                      </h3>
                      <p>
                        {isUaePage
                          ? 'A European biotech used a mixed-method UAE study (oncology survey plus KOL interviews and payer input) to validate launch viability, refine pricing assumptions, and prioritize advisory board engagement.'
                          : isSaudiPage
                            ? 'A biosimilar manufacturer used physician and payer evidence to optimize public-sector tender positioning, refine pricing logic, and accelerate adoption planning across key oncology accounts.'
                            : isUsPage
                              ? 'A biotech team used physician segmentation and payer advisory research to refine launch sequencing and improve early adoption confidence for an oncology asset.'
                              : isUkPage
                                ? 'A biotech program used UK consultant and health-economic insight to strengthen NICE submission evidence and improve early NHS access confidence.'
                                : isGermanyPage
                                  ? 'An oncology launch team used German specialist and stakeholder evidence to improve positioning, comparator framing, and early account activation.'
                                  : isFrancePage
                                    ? 'An oncology launch team used French specialist and stakeholder evidence to improve positioning, evidence framing, and early account activation.'
                                    : isSpainPage
                                      ? 'An oncology launch team used Spanish specialist and stakeholder evidence to improve positioning, evidence framing, and early account activation.'
                                      : isItalyPage
                                        ? 'An oncology launch team used Italian specialist and stakeholder evidence to improve positioning, evidence framing, and early account activation.'
                                      : isKuwaitPage
                                        ? 'An oncology launch team used MOH and private-hospital insight in Kuwait to improve formulary sequencing, stakeholder alignment, and early account activation.'
                                    : isQatarPage
                                      ? 'An oncology launch team used public-private stakeholder evidence in Qatar to improve market access sequencing and early account activation.'
                                    : isBahrainPage
                                      ? 'An oncology launch team used Bahrain physician and stakeholder evidence to strengthen positioning and early adoption planning.'
                                    : isOmanPage
                                      ? 'An oncology launch team used Oman specialist and institutional insight to improve positioning and launch adoption readiness.'
                                      : 'An oncology launch team used MOH and university-hospital insight in Egypt to improve positioning, stakeholder sequencing, and early account activation.'}
                      </p>
                    </div>
                    <div>
                      <h3 className="text-lg font-semibold text-foreground mb-2">
                        {isUaePage
                          ? 'Case Study 2: Diabetes Access Strategy'
                          : isSaudiPage
                            ? 'Case Study 2: Orphan Drug Access Pathway'
                            : isUsPage
                              ? 'Case Study 2: Payer and PBM Access Strategy'
                              : isUkPage
                                ? 'Case Study 2: Rare Disease Specialized Commissioning Strategy'
                                : isGermanyPage
                                  ? 'Case Study 2: AMNOG-Aligned Rare Disease Strategy'
                                  : isFrancePage
                                    ? 'Case Study 2: HTA-Aligned Rare Disease Strategy in France'
                                    : isSpainPage
                                      ? 'Case Study 2: HTA-Aligned Rare Disease Strategy in Spain'
                                      : isItalyPage
                                        ? 'Case Study 2: AIFA-Aware Rare Disease Strategy in Italy'
                                      : isKuwaitPage
                                        ? 'Case Study 2: Kuwait Diabetes and Cardiometabolic Access Strategy'
                                    : isQatarPage
                                      ? 'Case Study 2: Qatar Cardiometabolic Access Strategy'
                                    : isBahrainPage
                                      ? 'Case Study 2: Bahrain Rare Disease Access Strategy'
                                    : isOmanPage
                                      ? 'Case Study 2: Oman Cardiometabolic Access Strategy'
                                      : 'Case Study 2: Egypt Hepatology and HCV Program Strategy'}
                      </h3>
                      <p>
                        {isUaePage
                          ? 'A top global pharma team used endocrinologist and payer intelligence to optimize GLP-1 access sequencing and accelerate formulary progress through UAE private and national insurance channels.'
                          : isSaudiPage
                            ? 'A rare-disease biotech used KOL mapping and regulatory intelligence to improve pathway design for orphan access and accelerate evidence-backed stakeholder engagement in Saudi Arabia.'
                            : isUsPage
                              ? 'A specialty portfolio used Medicare and commercial access research to optimize value messaging, utilization-management mitigation, and formulary engagement timing.'
                              : isUkPage
                                ? 'A rare-disease team used UK specialist-centre mapping and commissioning intelligence to improve patient identification and access pathway readiness.'
                                : isGermanyPage
                                  ? 'A rare-disease program used evidence-priority and stakeholder mapping in Germany to strengthen access readiness and launch confidence.'
                                  : isFrancePage
                                    ? 'A rare-disease program used evidence-priority and stakeholder mapping in France to strengthen access readiness and launch confidence.'
                                    : isSpainPage
                                      ? 'A rare-disease program used evidence-priority and stakeholder mapping in Spain to strengthen access readiness and launch confidence.'
                                      : isItalyPage
                                        ? 'A rare-disease program used evidence-priority and stakeholder mapping in Italy to strengthen access readiness and launch confidence.'
                                      : isKuwaitPage
                                        ? 'A diabetes portfolio used physician and tender intelligence in Kuwait to refine pricing assumptions, formulary strategy, and private-channel activation.'
                                    : isQatarPage
                                      ? 'A cardiometabolic portfolio used physician and payer insight in Qatar to refine value messaging, access planning, and channel activation.'
                                    : isBahrainPage
                                      ? 'A rare-disease program used Bahrain stakeholder mapping and evidence prioritization to strengthen access readiness and launch confidence.'
                                    : isOmanPage
                                      ? 'A cardiometabolic portfolio used Oman physician and channel intelligence to optimize access sequencing and adoption planning.'
                                      : 'A hepatology program used physician and diagnostics insight in Egypt to refine patient-flow assumptions, evidence priorities, and access planning.'}
                      </p>
                    </div>
                    <div>
                      <h3 className="text-lg font-semibold text-foreground mb-2">
                        {isUaePage
                          ? 'Case Study 3: Rare Disease KOL Mapping'
                          : isSaudiPage
                            ? 'Case Study 3: Diabetes Market Access Optimization'
                            : isUsPage
                              ? 'Case Study 3: Competitive Intelligence Activation'
                              : isUkPage
                                ? 'Case Study 3: UK Primary Care and Formulary Adoption Optimization'
                                : isGermanyPage
                                  ? 'Case Study 3: Germany Competitive Intelligence and Adoption Optimization'
                                  : isFrancePage
                                    ? 'Case Study 3: France Competitive Intelligence and Adoption Optimization'
                                    : isSpainPage
                                      ? 'Case Study 3: Spain Competitive Intelligence and Adoption Optimization'
                                      : isItalyPage
                                        ? 'Case Study 3: Italy Competitive Intelligence and Adoption Optimization'
                                      : isKuwaitPage
                                        ? 'Case Study 3: Kuwait Tender and Private Sector Intelligence Activation'
                                    : isQatarPage
                                      ? 'Case Study 3: Qatar Competitive Intelligence and Adoption Optimization'
                                    : isBahrainPage
                                      ? 'Case Study 3: Bahrain Competitive Intelligence and Adoption Optimization'
                                    : isOmanPage
                                      ? 'Case Study 3: Oman Competitive Intelligence and Adoption Optimization'
                                      : 'Case Study 3: Egypt Diagnostics and Lab-Network Intelligence'}
                      </h3>
                      <p>
                        {isUaePage
                          ? 'A rare-disease biotech established a UAE advisory structure with specialist mapping, diagnosis-flow analysis, and advocacy planning to improve education and patient identification pathways.'
                          : isSaudiPage
                            ? 'A global pharma team used endocrinology and payer evidence to sequence public and private access efforts for GLP-1 therapies and improve formulary traction.'
                            : isUsPage
                              ? 'A US launch team used awareness tracking, message testing, and segment-level response analytics to improve positioning and accelerate adoption in priority accounts.'
                              : isUkPage
                                ? 'A diabetes launch program used GP and specialist evidence to improve referral behavior, regional formulary planning, and practical NHS implementation speed.'
                                : isGermanyPage
                                  ? 'A launch analytics program in Germany used segment-level tracking and message refinement to improve adoption across specialty and ambulatory channels.'
                                  : isFrancePage
                                    ? 'A launch analytics program in France used segment-level tracking and message refinement to improve adoption across specialty and ambulatory channels.'
                                    : isSpainPage
                                      ? 'A launch analytics program in Spain used segment-level tracking and message refinement to improve adoption across specialty and ambulatory channels.'
                                      : isItalyPage
                                        ? 'A launch analytics program in Italy used segment-level tracking and message refinement to improve adoption across specialty and ambulatory channels.'
                                      : isKuwaitPage
                                        ? 'A Kuwait launch program used MOH tender tracking and private-hospital feedback loops to optimize positioning and speed adoption across high-priority accounts.'
                                    : isQatarPage
                                      ? 'A Qatar launch program used segment-level tracking and message optimization to improve adoption across public and private care pathways.'
                                    : isBahrainPage
                                      ? 'A Bahrain launch program used competitive tracking and message refinement to improve adoption across priority specialty channels.'
                                    : isOmanPage
                                      ? 'An Oman launch program used awareness tracking and pathway insight to improve adoption across institutional and private-care channels.'
                                      : 'A diagnostics-led study across Egyptian laboratory networks improved testing-pathway understanding and strengthened launch execution for chronic-disease portfolios.'}
                      </p>
                    </div>
                  </div>
                </article>

                <article id="uae-faq" className="bg-card border border-border rounded-xl p-6 md:p-8">
                  <h2 className="text-2xl font-display font-semibold text-foreground mb-4">Frequently Asked Questions</h2>
                  <div className="space-y-3">
                    {(isUaePage ? UAE_FAQS : isSaudiPage ? SAUDI_FAQS : isUsPage ? US_FAQS : isUkPage ? UK_FAQS : isGermanyPage ? GERMANY_FAQS : isFrancePage ? FRANCE_FAQS : isSpainPage ? SPAIN_FAQS : isItalyPage ? ITALY_FAQS : isKuwaitPage ? KUWAIT_FAQS : isQatarPage ? QATAR_FAQS : isBahrainPage ? BAHRAIN_FAQS : isOmanPage ? OMAN_FAQS : EGYPT_FAQS).map((item) => (
                      <details key={item.question} className="rounded-lg border border-border px-4 py-3">
                        <summary className="cursor-pointer font-medium text-foreground">{item.question}</summary>
                        <p className="mt-3 text-muted-foreground leading-relaxed">{item.answer}</p>
                      </details>
                    ))}
                  </div>
                </article>

                <article id="related-resources" className="bg-card border border-border rounded-xl p-6 md:p-8">
                  <h2 className="text-2xl font-display font-semibold text-foreground mb-4">Related Resources</h2>
                  <div className="grid md:grid-cols-2 gap-3">
                    <Link
                      to={isUaePage ? '/market-research-saudi-arabia-pharmaceutical' : isSaudiPage ? '/global-websites/united-arab-emirates' : isUsPage ? '/global-websites/united-kingdom' : isUkPage ? '/global-websites/germany' : isGermanyPage ? '/global-websites/france' : isFrancePage ? '/global-websites/spain' : isSpainPage ? '/global-websites/italy' : isItalyPage ? '/global-websites/kuwait' : isKuwaitPage ? '/global-websites/qatar' : isQatarPage ? '/global-websites/bahrain' : isBahrainPage ? '/global-websites/oman' : '/global-websites/saudi-arabia'}
                      className="text-primary hover:underline"
                    >
                      {isUaePage
                        ? 'Saudi Arabia Pharmaceutical Market Research'
                        : isSaudiPage
                          ? 'UAE Pharmaceutical Market Research'
                          : isUsPage
                            ? 'Saudi Arabia Pharmaceutical Market Research'
                            : isUkPage
                              ? 'United States Pharmaceutical Market Research'
                              : isGermanyPage
                                ? 'France Pharmaceutical Market Research'
                                : isFrancePage
                                  ? 'Spain Pharmaceutical Market Research'
                                  : isSpainPage
                                    ? 'Italy Pharmaceutical Market Research'
                                    : isItalyPage
                                      ? 'Kuwait Pharmaceutical Market Research'
                                    : isKuwaitPage
                                      ? 'Qatar Pharmaceutical Market Research'
                                    : isQatarPage
                                      ? 'Bahrain Pharmaceutical Market Research'
                                    : isBahrainPage
                                      ? 'Oman Pharmaceutical Market Research'
                                    : 'Saudi Arabia Pharmaceutical Market Research'}
                    </Link>
                    {isKuwaitPage || isQatarPage || isBahrainPage || isOmanPage ? (
                      <>
                        <Link to="/global-websites/qatar" className="text-primary hover:underline">
                          Qatar Pharmaceutical Market Research
                        </Link>
                        <Link to="/global-websites/united-arab-emirates" className="text-primary hover:underline">
                          UAE Pharmaceutical Market Research
                        </Link>
                        <Link to="/global-websites/saudi-arabia" className="text-primary hover:underline">
                          Saudi Arabia Pharmaceutical Market Research
                        </Link>
                      </>
                    ) : isEgyptPage ? (
                      <>
                        <Link to="/global-websites/united-arab-emirates" className="text-primary hover:underline">
                          UAE Pharmaceutical Market Research
                        </Link>
                        <Link to="/global-websites/qatar" className="text-primary hover:underline">
                          Qatar Pharmaceutical Market Research
                        </Link>
                      </>
                    ) : null}
                    <Link to="/healthcare-market-research" className="text-primary hover:underline">
                      Healthcare Market Research Hub
                    </Link>
                    <Link to="/services/quantitative-research" className="text-primary hover:underline">
                      Quantitative Research Services
                    </Link>
                    <Link to="/services/qualitative-research" className="text-primary hover:underline">
                      Qualitative Research Services
                    </Link>
                    <Link to="/services/market-access" className="text-primary hover:underline">
                      Market Access and HTA Strategy
                    </Link>
                    <Link to="/services/kol-stakeholder-mapping" className="text-primary hover:underline">
                      KOL and Stakeholder Mapping
                    </Link>
                  </div>
                </article>
              </div>
            </section>
          </>
        ) : (
          <>
            <section className="section-padding py-8 bg-muted/30">
              <div className="container-wide max-w-5xl mx-auto">
                <h2 className="text-2xl font-display font-semibold text-foreground mb-5">Market Table of Contents</h2>
                <ol className="grid md:grid-cols-2 gap-3">
                  {marketSections.map((section) => (
                    <li key={section.id} className="bg-card border border-border rounded-lg px-4 py-3">
                      <a href={`#${section.id}`} className="text-primary font-medium hover:underline">
                        {section.title}
                      </a>
                    </li>
                  ))}
                </ol>
              </div>
            </section>

            <section className="section-padding py-10">
              <div className="container-wide max-w-5xl mx-auto space-y-8">
                {marketSections.map((section) => (
                  <article key={section.id} id={section.id} className="bg-card border border-border rounded-xl p-6 md:p-8">
                    <h2 className="text-2xl font-display font-semibold text-foreground mb-4">{section.title}</h2>
                    <div className="space-y-4 text-muted-foreground leading-relaxed">
                      {section.paragraphs.map((paragraph, idx) => (
                        <p key={`${section.id}-${idx}`}>{paragraph}</p>
                      ))}
                    </div>
                  </article>
                ))}
              </div>
            </section>
          </>
        )}

        <section className="section-padding py-10 bg-muted/30">
          <div className="container-wide max-w-5xl mx-auto">
            <h2 className="text-2xl font-display font-semibold text-foreground mb-5">Work with BioNixus</h2>
            <div className="grid md:grid-cols-2 gap-4">
              <Link
                to="/services"
                className="inline-flex items-center justify-center gap-2 px-6 py-4 rounded-xl bg-primary text-primary-foreground font-semibold hover:bg-primary/90 transition-colors"
              >
                Explore Services
                <ArrowRight className="w-4 h-4" />
              </Link>
              <Link
                to="/contact"
                className="inline-flex items-center justify-center gap-2 px-6 py-4 rounded-xl border border-border bg-card text-foreground font-semibold hover:bg-muted transition-colors"
              >
                Contact BioNixus
                <ArrowRight className="w-4 h-4" />
              </Link>
            </div>
          </div>
        </section>

        {!isUaePage && !isSaudiPage && !isUsPage && !isUkPage && !isGermanyPage && !isFrancePage && !isSpainPage && !isItalyPage && !isKuwaitPage && !isQatarPage && !isBahrainPage && !isOmanPage && !isEgyptPage ? (
          <>
            <section className="section-padding py-10 bg-muted/20">
              <div className="container-wide max-w-5xl mx-auto">
                <h2 className="text-2xl font-display font-semibold text-foreground mb-4">Frequently Asked Questions</h2>
                <div className="space-y-3">
                  {genericFaq.map((item) => (
                    <details key={item.question} className="rounded-lg border border-border bg-card px-4 py-3">
                      <summary className="cursor-pointer font-medium text-foreground">{item.question}</summary>
                      <p className="mt-3 text-muted-foreground leading-relaxed">{item.answer}</p>
                    </details>
                  ))}
                </div>
              </div>
            </section>

            {relatedCountries.length > 0 ? (
              <section className="section-padding py-10">
                <div className="container-wide max-w-5xl mx-auto">
                  <h2 className="text-2xl font-display font-semibold text-foreground mb-4">Related country pages</h2>
                  <div className="grid md:grid-cols-2 gap-3">
                    {relatedCountries.map((item) => (
                      <Link
                        key={item.slug}
                        to={`/global-websites/${item.slug}`}
                        className="rounded-lg border border-border bg-card p-4 text-primary hover:border-primary/40 transition-colors"
                      >
                        {item.countryName} pharmaceutical market research
                      </Link>
                    ))}
                  </div>
                </div>
              </section>
            ) : null}
          </>
        ) : null}

        <section className="section-padding py-10">
          <div className="container-wide max-w-5xl mx-auto">
            <Link to={basePath} className="inline-flex items-center gap-2 text-primary font-medium hover:underline">
              <ArrowLeft className="w-4 h-4" /> Return to home
            </Link>
          </div>
        </section>
      </main>

      <Footer />
    </div>
  );
};

export default GlobalWebsiteCountry;
